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G Stellingen bij het proefschrift 
L--------l 
PET and SPECT imaging of bone marrow disorders 
door Ali Agool 
1. 18F-FLT-PET kan gebruikt warden om de proliferatieve activiteit van het beenmerg 
compartiment aan te tonen en kan van nut zijn om separate hematologische 
aandoeningen te onderscheiden (dit proefschrift ). 
2. 18F-FLT-PET bevestigt de significant verhoogde proliferatieve activiteit van de CD34+ 
celfractie na een autologe stamceltransplantatie (dit proefschrift ). 
3. 18F-FLT-PET is een aantrekkelijke niet-invasieve techniek voor het aantonen van 
extramedullaire hematopoiesis (dit proefschrift). 
4. Somatostatine receptor scintigrafie is een waardevolle techniek om myeloom 
activiteit te detecteren, vooral bij hernieuwde ziekteactiviteit (dit proefschrift). 
5. Analyse van al de somatostatine receptor subtypen op myeloom cellen kan de eerste 
stap zijn richting radionuclide therapie. (dit proefschrift). 
6. 18F-FLT-PET lijkt accurater te zijn dan 18F-FDG-PET in de differentiatie tussen tumor 
versus ontstekingsaktiviteit. 
Tae Sup Lee, Nuclear Medicine and Biology, 2009;36:681-686 
7. De bijdrage van nucleaire onderzoekingen aan de effectieve volgdosis per persoon 
per jaar in Nederland is gering ten opzichte van de overige bronnen. 
RIVM, lnformatiesysteem Medische Stralingstoepassingen, versie 7.0, 3 juni 2010 
8. One of the first duties of the physician is to educate the masses not to take medicine 
William Osler 
9. Als dit universum in zijn miljoenvoudige orde en precisie het resultaat van blind 
toeval zou zijn, dan is dat net zo geloofwaardig als wanneer een drukkerij explodeert 
en alle druklettertjes weer op de grand terecht komen in de voltooide en foutloze 
vorm van het woordenboek. 
Albert Einstein 
10. Het belangrijkste bij communicatie, is horen wat niet wordt gezegd. 
Peter Drucker 
11. lk sliep en droomde dat het leven vreugde was; ik ontwaakte en zag: het leven is 
plicht; ik werkte en zei: de plicht is vreugde. 
Saadi 
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GENERAL INTRODUCTION AND SCOPE OF THIS THESIS 
General introduction In the bone marrow different hematopoietic cells are produced that originate from a limited number of hematopoietic stem cells. These cells are not only intrinsically instructed but are also strongly modulated by surrounding cells including osteoblasts, adipocytes and sinus-endothelial cells that together forms the micro-environment. Depending on the type of disease different disorders can be recognized, including myelodysplasia, aplastic anemia and myelofibrosis. Non invasive imaging techniques have been used in the past for visualization of the functional activity of the bone marrow compartment as 99mTc-nanocolloid, 99mTc-sulphur colloid, 1IIIndium-chloride, and radiolabeled white blood cells. With these techniques the reticulo-endothelial system, the erythroid and the myeloid­compartment can be recognized. The recent development in research and clinical use of PET tracers make it possible to analyze additional properties such as cellular metabolism and proliferative activity by using 1sF-FDG and IsF-FLT. 18F-FDG is a glucose analogue that enters the cell and resembles the glucose metabolism in activated cell processes, especially in malignant disorders. 1sF-FLT is used to study the proliferative activity, and is also mainly used in malignant disorders. A positive correlation has been found between the FLT uptake and the proliferative activity of normal and malignant tissue. The FLT uptake is more specific compared to 1sF-FDG. The aim of this thesis is to evaluate new applications of 1sF-FDG and 1sF-FLT- PET in patients with various haematological disorders. 
Scope of this thesis In chapter 2 the background of several hematological disorders are discussed. Different bone marrow targets imaged with radionuclides, including PET tracers are described. Current indications for radionuclide bone marrow imaging are listed. Chapter 3 demonstrates the feasibility of visualisation and quantification of the bone marrow compartment activity with sF-FLT-PET to distinguish different haematological disorders. The role of 1 sF-FLT-PET in myelodysplasia, myelofibrosis, and myeloproliferative disorders are studied. The uptake, distribution, and extension of 1sF-FLT are compared with a control group. 13 
CHAPTER I In chapter 4 the long term effects of autologous stem cell transplantation on the haematopoietic stem cell compartment is investigated. Phenotypical changes in the composition of progenitor subsets are studied and the enhanced in vivo cycling activity is compared to the 1sF-FLT PET. The intensity of the uptake, distribution, and extension are investigated and compared with a control group. In chapter 5 a distinctive overview of the bone marrow compartment in aplastic anemia (AA) is investigated by using 1 sF-FLT-PET. The 1sF-FLT-PET patterns are assessed in two groups of AA patients i.e. patients with active disease and following treatment. Chapter 6 describes the role of 1sF-FLT-PET in patients following radio- and chemotherapy. Two groups of patients are studied Patients with laryngeal carcinoma and patients with metastatic nonseminomatous testicular germ cell tumor treated with radio­and chemotherapy is investigated respectively. The uptake of 1sF-FLT in the affected area due to therapy is compared to a control group. Chapter 7 describes a case report about the role of the 1sF-FLT-PET in detecting extramedullary haematopoiesis in a patient with �-thalassemia. Chapter 8 demonstrates the role of the somatostatin receptor scintigraphy (SRS) as a tool to detect multiple myeloma activity in newly diagnosed and relapsing multiple myeloma patients. Also the effect of therapy on disease activity is monitored by repeating SRS after 3-4 months of treatment. Chapter 9 provides a summary of the thesis, and the results are discussed as well as potential future prospectives. 14 
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CHAPTER2 
Abstract 
Non invasive imaging techniques have been used in the past for visualization the functional 
activity of the bone marrow compartment. Imaging with radiolabeled compounds offers 
the opportunity to make a distinction between separate bone marrow disorders. These 
imaging techniques, almost all with the use of radionuclide labeled tracers, such as 99rnTc­
nanocolloid, 99rnTc-sulphur colloid, 1 1 1Indium-chloride, and radiolabeled white blood cells, 
are already used in nuclear medicine for several decades. With these techniques three 
separate compartments can be recognized including the reticulo-endothelial system, the 
erythroid and the myeloid-compartment. The recent development in research and clinical 
use of PET tracers make it possible to analyze additional properties such as cellular 
metabolism, and proliferative activity, by using 18F-FDG and 18F-FLT. These tracers may 
lead to better quantification and targeting of different cell systems in the bone marrow. In 
this review imaging of different bone marrow targets with radionuclides, including PET 
tracers will be discussed in various bone marrow diseases. 
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Introduction 
Bone marrow is a dynamic tissue compartment in the cavity of bones. In adults, 
hematopoietic cells are produced by the bone marrow cells in the large bones that 
accounts for 2 to 5% of an adult's weight [1]. In the past, a distinction was made between 
red marrow which consists of hematopoietic cells and yellow marrow which consists 
of adipocytes. It is now general accepted that a small fraction of cells, the so-called 
hematopoietic stem cells (HSCs) reside in specific areas of the bone marrow including 
the osteoblastic and vascular niche [ 1]. These HSC have the potential of self-renewal but 
also to proliferate and differentiate to the different cell lineages including the myeloid, 
erythroid and megakaryocytic lineage [2]. This process is strongly dependent on 
surrounding cells of the microenvironment including mesenchymal stem cells that have 
the capacity to differentiate into osteoblasts, chondrocytes, adipocytes, myocytes, and 
endothelial cells [ 1]. During life distinct changes occur in the composition of the bone 
marrow cavity. At birth, the whole bone marrow cavity contains hematopoietic cells 
which are gradually replaced by adipose tissue during life. Especially the distal parts 
of the skeleton are depleted from hematopoietic cells upon ageing. The architecture of 
the hematopoietic system can be distorted strongly by a number of disorders, including 
malignancy. Transformation of a hematopoietic stem cell can result in the expansion of 
the malignant clone and a disruption of the normal hematopoietic system [3]. In acute 
leukemia the bone marrow contains a population of immature cells that has lost the 
potential to differentiate. For myeloproliferative disorders however, there is an expansion 
of a certain hematopoietic lineage that has the persisting potential of differentiation [ 4]. 
Exposure to radiation or chemotherapy for both hematological malignancies as well as 
solid tumors will eliminate many of the rapidly dividing cells of the bone marrow. The 
degree and extent of this process will determine the severity of the bone marrow aplasia 
and duration of peripheral pancytopenia. Limited diagnostic procedures are available 
to determine the extent of bone marrow involvement. It is assumed that the material 
obtained with a bone marrow aspiration and biopsy from the sternum or the crista 
iliaca are a reflection of the total bone marrow compartment. Using these methods, its 
composition and cellular components can be analyzed. In addition, in vitro assays can be 
used to measure the potential of more primitive progenitors or stem cells [5]. However, 
bone marrow biopsy has distinct limitations: it is an invasive procedure and only a 
small proportion of the total bone marrow content is investigated. The latter may cause 
17 
CHAPTER2 sampling errors. A non invasive technique to evaluate the total bone marrow activity in hematological diseases, as well as for the evaluation of hematological effects concerning solid tumors is therefore of invaluable importance. In this review we will describe the clinical indications of bone marrow imaging as well as the most common bone marrow disorders, including bone marrow transplantation. This is combined with a review of the literature on nuclear medicine techniques that are used in diagnostic protocols for determination of bone marrow disorders. There will be special attention on recent development of Positron Emitting Tomography (PET) techniques to image the bone marrow. 
Clinical indications A list of current indications for radionuclide bone marrow imaging are listed in table 1. Bone marrow aspiration and biopsy are usually the standard techniques for evaluation of the bone marrow function. However, sometimes a discrepancy can be found between histology of the bone marrow and patients' lab and clinical findings. This may be due to a bone marrow sampling error. Non invasive imaging using a specific bone marrow tracer can be helpful to confirm a suspected sampling error and will visualize a specific part of bone marrow functionality. Many patients suffering from malignancies are treated with chemotherapy and/ or radiotherapy. These therapy modalities commonly cause adverse events on bone marrow activity. Bone marrow imaging may determine the amount of remaining functional bone marrow tissue and shows its biodistribution. Extramedullary hematopoiesis (EMH) refers to hematopoiesis taking place outside the bone marrow. This is a symptom for several hematologic disorders, including chronic hemolytic anemia and myeloproliferative disorders. EMH is mainly present in liver and spleen, where it contributes to organ enlargement. It may however also occur within other organs or structures [6]. Clinical arguments supporting evaluation of EMH can be 1) to determine the extent of EMH in liver or spleen, 2) to evaluate the presence and contribution of splenic erythropoiesis in patients under consideration for splenectomy, and 3) to evaluate mass lesions outside liver and spleen to differentiate from other processes. Bone marrow imaging is a diagnostic tool for determination and staging of 
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several hematologic bone marrow disorders. The latter will be further addressed in the 
next paragraph "Bone marrow disorders". 
Detection of bone marrow activity as well as bone metastases is another indication for 
bone marrow imaging. Solid tumors have the propensity to metastasize to bone and may, 
therefore, influence the bone marrow compartment. Appropriate radiopharmaceuticals and 
clinical results are discussed in section "Imaging the bone marrow using radionuclides". 
Bone marrow infarctions are common in patients with sickle cell anemia and its variants 
S-C and S-thalassemia. Thalassemia is an inherited autosomal recessive blood disease. 
Patients with hemoglobin SC disease inherit a gene for hemoglobin S from one parent, 
and a gene for hemoglobin C from the other. In fact, more than half of all patients suffering 
from-these pathologies will experience bone marrow infarctions at a particular time point 
during the course of their disease [7]. Plain X-ray images are usually normal in acute bone 
marrow infarction; therefore, radionuclide imaging can play an additional role for the 
detection of acute bone marrow infarctions [8]. Finally, bone marrow imaging techniques 
may be useful to study the proliferative activity of the hematopoietic compartment 
following intensive chemotherapy with and without stem cell support. Especially in the 
setting of autologous stem cell transplantation, determination of the remaining activity 
of the hematopoietic activity and its susceptibility for chemotherapeutic intervention 
in the case of relapse may be valuable. Bone marrow imaging may also be indicated to 
differentiate sepsis from bone marrow, after unclear skeletal and leukocytes scintigraphy 
findings, however this will be beyond the scope of this review. 
1Q 
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Table 1: Indications for bone marrow imaging 1. Evaluation of patients with a discrepancy between bone marrow histology and clinical status 2. Evaluation of the degree of radiotherapy effect on bone marrow 3. Detection of extramedullary hematopoiesis 4. Location of the optimal site for bone marrow biopsy 5. Diagnosing and staging of hematologic bone marrow disorders 6. Detection of bone marrow metastases 7. Diagnosis of bone marrow infarctions 8. Evaluation of bone marrow transplantation 
Bone marrow disorders 
Myeloproliferative diseases Myeloproliferative diseases (MPDs) are clonal hematopoietic stem cell disorders characterized by proliferation in the bone marrow of one or more cell lines resulting in an excessive production of cells belonging to the granulocytic, erythroid and megakaryocytic lineage (table 2). Nowadays, a WHO classification is used for making a distinction between the separate disorders [9]. Different molecular markers have been defined such as JAK2 and TET2 mutations that might further be helpful in categorizing the disorders [10]. Most frequently diagnosed are chronic myeloid leukemia, polycythemia vera, chronic idiopathic myelofibrosis, and essential thrombocythemia [11]. These disorders are characterized by the fact that enhanced proliferation of different cell lines is accompanied with a relatively normal maturation, resulting in increased number of granulocytes, red blood cells and/or platelets in the peripheral blood. MPDs are mainly occurring in adult population with higher prevalence in the fifth to seventh decade of life. The MPDs can have a stepwise progression that is leading to bone marrow failure due to myelofibrosis or ineffective hematopoiesis. Furthermore, transformation to acute leukemia may occur. 
20 
RADIONUCLIDE IMAGING OF BONE MARROW DISORDERS Frequently, there is a coincidence of symptoms for the specific MDP entities. Leukocytosis, thrombocytosis, excessive megakaryocytic proliferation, myelofibrosis and organomegaly are features that can occur in almost any of the MDP diseases. For example, both polycythemia vera (malignant red blood cell proliferation) and myelofibrosis (MF, proliferation of mainly megakaryocytic elements, associated with deposition of bone marrow connective tissue) can also be associated with increased white blood cells. Polycythemia vera (PV ) is usually associated with a mild increase in white blood cell counts. The latter is associated with a regular white blood cell differentiation, whereas myelofibrosis is frequently associated with a mild increase of immature white blood cells. Leukocytosis in PV is associated with an increased risk of thrombosis. However, the primarily treatment is directed towards the control of increased red blood cells [12]. Today there remains a distinct subgroup of elderly patients with polycythaemia vera for whom 32P is the most optimal treatment option, as described in the guideline of the EANM [13]. MF is associated with variable abnormalities in white blood cells, either increased with circulating immature precursors, or decreased in the presence of massive splenomegaly. The number of white blood cells in MF is therefore important for treatment decisions. Recently, a prognostic score index has been defined that may be helpful for ad justing the proper treatment [ 14]. For example in PV, a survival time longer than 10 years is not uncommon [ 11]. The recent development of therapy targeting specific molecular defects in MPDs is an exiting field of interest in which nuclear medicine can play a key role. 21 
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Table 2: Features of myeloid disorders at diagnosis. 
Disease BM Blasts Maturation Morpho- Hemato Blood Organo-
cellularity logy poiesis counts megaly 
Myelodys- Usually Normal or Present Dysplasia Ineffective Cytopenia Uncommon 
plastic increased , increased 
syndromes occasionally ( <20%) 
decreased 
Myelo- Usually Normal Present Relatively Effective One or more Common 
proliferative increased or slightly normal myeloid cell 
disorders increased lines in-
(<10%) creased 
Acute Usually Increased Varies , Sometimes Ineffective Variable Uncommon 
myeloid increased , (>20%) frequently associated or effective 
leukemia occasionally minimal with 
decreased dysplasia 
Myelodysplastic syndromes 
Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell diseases 
characterized by dysplasia and ineffective hematopoiesis in one or more of the major 
cell lines (table 2). The clinical behavior of MDS can be highly variable and separation 
in subgroups is based on the bone marrow cytology and cytogenetic findings according 
to the WHO classification [9,15]. Subgroups that can be distinguished are refractory 
anemia (with or without ringed sideroblasts) , refractory cytopenia with multilineage 
dysplasia , refractory anemia with excess of blasts , and myelodysplastic syndrome 
(unclassified or with a chromosome abnormality). MDS occurs predominantly in older 
adults with a median age of 70 years. Secondary MDS, a result of chemotherapy and/or 
radiotherapy for other malignant disorders , is an increasing problem and may represent 
as many as 15% of all MDS diagnosed [16]. Secondary MDS tends to be much more 
severe than primary MDS. Clinical symptoms are related to cytopenia(s) , most frequently 
anemia , and less commonly neutropenia and/or thrombocytopenia. Organomegaly 
is infrequently observed. MDS prognosis depends on its morphological subtype and 
cytogenetic characteristics by which patients can be subdivided in low- and high- risk 
group. The low-risk group is treated with transfusion, hematopoietic growth factors, 
immunosuppressive therapy or lenolidamide . The high risk group is treated in general 
22 
RADIONUCLIDE IMAGING OF BONE MARROW DISORDERS with therapy regimens, commonly used for patients with acute leukemia including allogeneic stem cell transplantation [ 17]. Aplastic anemia Aplastic anemia (AA) is a rare hematological disorder caused by immune-mediated destruction of hematopoietic stem cells in the bone marrow [18]. Hematopoiesis fails, blood cell counts are extremely low (pancytopenia) and the bone marrow appears empty. Massive AA is a life-threatening bone marrow disorder, which is associated - if untreated - with high mortality rates [19]. Almost half of AA-cases occur during the first three decades of life. Often, the etiology remains unclear. AA is associated with exposure to toxins such as benzene, or with the use of certain drugs, such as chloramphenicol, carbamazepine, phenytoin, and quinine. AA is present in up to 2% of patients with acute viral hepatitis. Clinical symptoms are related to the cytopenia(s).Anemia leads to malaise, pallor and related symptoms such as palpitations, thrombocytopenia to an increased risk of hemorrhage, bruising and petechia, and granulocytopenia to an increased risk of infection. AA can be effectively treated by immunosuppressive therapy or allogeneic stem cell transplantation. When initial treatment is started promptly, the five year survival rate is up to 75%. Patients after well-matched bone marrow transplantation, have a long­term survival rate of up to 90% [20]. Hemolytic anemia Hemolytic anemia (HA) is anemia due to the abnormal breakdown of red blood cells either in the blood vessels (intravascular hemolysis) or extravascular by an overactive, enlarged spleen that traps circulating red blood cells and destroys them. HA can be either acquired or inherited. Acquired HA can be either immune or non-immune mediated. HA represents approximately 5% of all anemia's. Signs of anemia (fatigue, palpitations and later heart failure) are generally present. Jaundice (as a result of bilirubin accumulation which is caused by hemoglobin degradation) can be the first sign. The overall incidence of death is low in cases of HA. However, older patients and patients with cardiovascular impairment are at higher risk compared to the rest of the population. Symptomatic treatment can be given by blood transfusion . In immune mediated HA steroid therapy is 
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highly effective. Splenectomy can be helpful in extravascular hemolysis, because in this 
case most red blood cells are removed by the spleen. 
Imaging the bone marrow using radionuclides 
Based on the target cell system, bone marrow imaging using radionuclides may be divided 
into three categories: ( 1 )  imaging the reticulo-endothelial system (RES) , (2) imaging 
erythroid precursor cells , and (3) imaging the myeloid compartment in the bone marrow. 
These imaging techniques , almost all using radionuclides for gamma cameras, have been 
already used in nuclear medicine for many years. The recent development in research 
and application of PET tracers lead to targeting two other pathways for imaging the bone 
marrow: (4) the metabolic activity, and (5) the proliferative activity. In general , PET 
tracers will provide absolute quantification options and a better resolution compared to 
gamma camera tracers. So the use of PET tracers may be an advantage compared to the 
use of gamma camera techniques for the evaluation of bone marrow disorders. The five 
target cell systems and the tracers for imaging the bone marrow will now be discussed. 
1 .  Imaging the reticulo-endothelial system 
The reticulo-endothelial system (RES) is part of the immune system and consists of 
phagocytic cells located in reticular connective tissue , primarily monocytes and 
macrophages. Major components of this system are the hepatic Kupffer 's cells , the 
phagocytic cells in the spleen and the phagocytic reticulum cells in the bone marrow. 
The RES can be easily imaged using radiolabeled colloids. Colloids are small particles 
that remain suspended in an appropriate solvent. After intravenous injection, they are 
phagocytosed by macrophages and distributed throughout the body in the RES. This 
property is used for RES targeted bone marrow scintigraphy. 
The two most widely used tracers for scintigraphy of the RES are 99mTc-sulfur colloid 
and 99mTc-nanocolloid. 99mTc-sulfur colloid is widely used in the United States. The size 
of the particles ranges from 100-1000 nm. After intravenous administration, 5% of the 
injected activity accumulates in the RES of the bone marrow, about 90% in the liver 
and 5% in the spleen [21 ]. Because of the high liver uptake it is difficult to evaluate 
the bone marrow in the lower thoracic and upper lumbar spine. 99mTc-nanocolloid is 
24 
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produced from microaggregated human serum albumin. More than 95% of the particles 
range below 80 nm. After intravenous injection, 99mTc-nanocolloid is rapidly cleared 
from plasma and taken up by the RES. About 15-20% is accumulated in the bone 
marrow by macrophages, the rest being distributed to the liver (70%) and spleen ( 10%) 
[22]. The small size of the nanocolloids causes an increased marrow uptake compared 
with the larger colloids. There is a small sized fraction of the nanocolloid which is not 
incorporated by RES and is probably slowly excreted by the kidneys, thereby giving rise 
to a considerable blood background and urinary tract activity. 
Normal bone marrow scintigraphy shows homogeneous activity in the bone marrow of 
the axial skeleton with uptake in the humeri and femora limited to the proximal one­
third. Skull, sternum and ribs may show a variable degree of uptake . The scans are 
evaluated for homogeneity and intensity of uptake in normally hematopoietic marrow­
containing structures, presence and extent of peripheral marrow expansion, central 
marrow depletion and focal marrow defects. Bone marrow infarctions due to sickle 
cell anemia can be imaged with 99mTc-sulphur colloid, since RES activity is lacking in 
infarcted bone marrow, showing demarcated defects in bone marrow [23]. In the past, 
bone marrow images were often obtained using nanocolloids. Currently, this method is 
not in use anymore because of its unfavourable target to background ratio [24]. 
2. Imaging the erythroid bone marrow ('the red cells') 
The erythropoietic part of the bone marrow can be imaged with the PET-tracer 52Fe. Iron 
is incorporated in the hemoglobin of erythrocytes. 
52Fe is a cyclotron-produced positron-emitting isotope with a half-life of 8.2 hours and 
decays by positron emission (57%) and by electron capture (43%) to the radioactive 
daughter 52mMn (table 3). Another iron radioisotope, 59Fe, emits �-rays with a high 
energy of 1,59 MeV and gamma rays of 1,1 and 1,3 MeV. It has a half-life of 45 days, 
and therefore imaging of low quality and a high radiation dose. Bone marrow expansion 
has been demonstrated in patients with chronic HA (not in acute HA), MF and, on 
rare occasions, with PV [25]. However, the aforementioned disadvantages, the limited 
availability of the isotope and PET facilities have precluded its widespread use. 
The tracer 1 1 1lndium-chloride ( 1 1 1ln-Cl3) distributes in the skeletal system partly similar 
to iron isotopes and partly like nanocolloids [26] . 1 1 1ln-Cl3 binds to transferrin in exactly 
the same manner as iron. The biological behavior of indium and iron is different, because 
25 
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In3+ is not reduced like iron to In2+ state , but in many respects they are similar, and 
marrow 1 1 1In-Cl3 uptake likely reflects the distribution of erythropoietic marrow. 
1 1 1In­
Cl3 has been used clinically for bone marrow studies [27 ,28]. It is a cyclotron-produced 
isotope with a half-life of 2 .8 days emitting gamma rays with energies of 171  (89%) and 
245 (94%) ke V. It decays by electron capture to the stable 1 1 1Cadmium. After intravenous 
injection, 1 1 1ln-Cl3 is rapidly coupled to serum transferrin and eliminated from plasma 
with a half-life of 5 hours. About 30% of the applied tracer is found in the bone marrow, 
20% in the liver, 7% in the kidneys, and 1 % in the spleen. The remaining activity is 
distributed throughout the body fluids without any specific tissue accumulation. 1 1 1In-Cl3 
is incorporated into erythrocytes only to a minor degree (4% of injected dose) [22]. In 
patients with normal bone marrow function and iron storage, the distribution of 1 1 1In-Cl3 
was similar to that of the 99mTc-labelled colloids (fig. 1) [26]. 
Patients with MF showed an extension of 1 1 1In-Cl3 uptake beyond the central skeleton 
towards the knees and sometimes ankles and elbows, together with uptake in the spleen. 
The clinical severity of the disease may be predicted by uptake of indium, particularly 
the disappearance of a physiologically active bone marrow (fig. 1) [29]. 1 1 1In-Cl3 
scintigraphy of the bone marrow was reported in patients with AA before therapeutic 
intervention. In almost all patients a marked reduction in the uptake was seen. Failure of 
1 1 1In-Cl3 uptake correlated with poor prognosis in patients with AA [30]. Another study 
was performed in patients with AA in remission for more than 2 years. Bone marrow 
scintigrams using 1 1 1In-Cl3 showed patchy hematopoiesis which appeared to characterize 
the residual marrow damage in remission of AA [31]. 
Overall , the results are not very encouraging. Moreover, bone marrow irradiated with 5 
Gy failed as expected to accumulate iron but had unimpaired 1 1 1ln-Cl3 uptake. Together 
with its nearly negligible incorporation into erythrocytes and the relatively high radiation 
exposure of the erythroid compartment , this almost completely precludes the use of 1 1 1In­




Table 3: Overview of different radiopharmaceuticals for imaging of the bone marrow. 
Radiopharmaceutical Physical Effective dose on Cyclotron 
half life bone marrow per 
MBq (mSv) 
Gammacamera 99mTc-sulfur colloid 6 h  0.00 19 99mTc-nanocolloid 6 h  0 .0094 1 1 1 Indium-chloride 2 .3 d 0 .21  99mTc-WBC 6 h  0 .023 
I I IJn-WBC 2 .3 d 0 .36 99mTc-AGAb 6 h  0.0055 
PET 
s2pe 8 .2 d 6 . 1  +/-1 8F-FDG 2 h  0 .0 1 1  +/-1 8F-FLT 2 h  0 .029 +/-






3. Imaging the myeloid bone marrow compartment (�the white cells') 
99mTc-HMPAO or 1 1 1In-oxinate labeled white blood cells (WBC) are useful bone marrow imaging tracers. As granulocytes may become damaged during the labeling process, they will be trapped in the marrow, so the obtained images presumably represent the distribution of marrow reticuloendothelial cells. Although there is considerable liver activity with this technique, it is significantly less than seen with the colloid agents so the spine is usually minimally obscured . However, the labor-intensive cell labeling procedure and risk of contamination makes this technique only suitable for well-equipped laboratories with qualified personnel. Labelling of WBC may be improved using new derived kits that are safe and easy to use methods, with a high labelling efficiency of WBC without affecting cell vitality and function and with less risk of contamination. An alternative technique to label WBC in-vivo is based on the use of antigranulocyte murine monoclonal antibodies, or Fab' fragments, labelled with 99mTc. 99mTc-labelled murine monoclonal antibodies have been developed to target granulocytes in vivo. Immunoscintigraphy using 99mTc-labelled antigranulocyte antibodies (99mTc-AGAb) directed against the non-specific cross reacting antigen 95 (NCA-95) has been found to be a suitable modality for bone marrow imaging because of the simplicity of its use and a high target-to-background ratio [32]. NCA-95 is expressed at the cell membrane of circulating granulocytes in blood as well as in matured myeloid cells in the bone marrow [33]. The binding of the AG Ab to cells in the bone marrow is very rapid and extensive because of the high concentration of granulocytes, promyelocytes and myelocytes that all express the NCA-95 antigen [34]. Myeloid cells in the bone marrow are in 50-100:1  excess compared with granulocytes in peripheral blood. 99mTc-AGAb was found to distribute primarily to bone marrow after intravenous injection [35], and a progressive increase in activity in the spleen and the bone marrow is visible [34]. The uptake in the spleen can potentially be used for assessment of extramedullary hematopoiesis [22]. The bone marrow status can be classified in three different ways: (a) estimation of the bone marrow distribution pattern, (b) identification of focal lesions (cold and hot), and (c) calculation of the uptake ratio between the sacroiliac region ( corrected for background activity) and the background [36]. The bone marrow appearance on 99mTc-AGAb scans seemed to be characteristic for the different hematological diseases. In PV, a moderately increased uptake in the spleen is described, probably related to extramedullary hematopoiesis [37]. In MDS, generalized, 
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RADIONUCLIDE IMAGING OF BONE MARROW DISORDERS small and focal defects in uptake of the bone marrow are described without indication of extramedullary hematopoiesis or peripheral expansion [22] . In patients with MF, diffusely decreased bone marrow activity and prominent splenic uptake was seen. In AA, highly reduced and patchy marrow uptake was observed , but also a diffusely decreased uptake. 
Figure 1: Different patterns of hematopoietic bone marrow imaging. A) Normal pattern of hematopoietic 
bone marrow activity in the central skeleton and skull; B) Expansion ofhematopoietic bone marrow activity 
more distal in the extremities; C) Reduced hematopoietic bone marrow activity in the central compartment 
of the skeleton and skull, as seen in aplastic anemia; D) Myelofibrosis with extramedullary erythropoiesis in 
spleen and liver and reduced hematopoietic bone marrow activity in the central compartment of the skeleton 
and skull . 29 
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4. Imaging of the metabolic activity The well known PET tracer 18P-Pluorodeoxyglucose ( 18P-FDG) is widely used in oncologic and infectious diseases. The 18P-FDG uptake is a measure of cell glucose utilization (glycolysis). 1 8P-FDG is metabolically trapped in the cell after phosphorylation to 18P-FDG-6-phosphate. Unlike glucose, 1 8P-FDG does not further participate in the glycolytic pathway and remains in the cell. 1 8F-FDG uptake reflects the metabolic activity of the cell and it is useful to examine the function of the red marrow and to detect bone marrow involvement in both benign and malignant disorders. PET-CT additionally provides the synergistic advantages of precise anatomic localization of radiotracer uptake, high contrast and spatial resolution, and accurate quantification of metabolic activity at sites of radiotracer uptake. Under normal conditions the liver, spleen, and bone marrow show homogeneous low uptake of 18P-FDG, with bone marrow and spleen appearing less intense than the liver. Uptake of 1 8F-FDG in hematopoietic marrow, and its pattern and amount can vary with age and with the level of marrow function at the time of PET examination [24]. 18P-FDG uptake in the bone marrow higher compared to the liver may indicate bone marrow activation. [38] This diffuse increase of 18P-FDG uptake in the bone marrow may be caused by the involvement of malignancy or hematopoietic disease but also due to an inflammatory reaction, stimulation by some types of malignancy, as a result of recent chemotherapy, or by the administration of hematopoietic growth factors. To determine efficacy of granulocyte colony-stimulating factor (G-CSP) and granulocyte-macrophage colony-stimulating factor (GM-CSP) on bone marrow glucose metabolism, the specific uptake of 18P-FDG in bone marrow was evaluated. It was shown that a substantial increase in bone marrow 18P-FDG uptake is rapidly induced by CSP treatments and should not be misinterpreted as diffuse bone metastases or bone marrow disease [39]. Therefore, 18F-FDG uptake is a sensitive marker of stimulated hematopoiesis , and both the extension and the intensification of uptake should be taken into account during hematopoietic growth factor (HGF) therapy [40]. 18P-FDG uptake in the bone marrow compartment can be quantified using the standardized uptake value (SUV). Patients with PV show a diffuse elevated 1 8P-FDG uptake in the bone marrow, as a result of bone marrow stimulation related to the clonal expansion of multi potent hematopoietic progenitor cells in this disease. When diffuse high marrow uptake of 18P-FDG is seen PV should be considered in the differential diagnosis in the absence of an another etiology 30 
RADIONUCLIDE IMAGING OF BONE MARROW DISORDERS [41,42]. A case report of a patient with MF showed a markedly increased 18F-FDG uptake throughout the spleen and liver. Both were massively enlarged, combined with a lower 
18F-FDG uptake in the bone marrow of the central skeleton, being a reflection of the patients' MF [43]. Patients with MDS also show diffuse bone marrow 18F-FDG uptake. The latter was also found in patients who underwent 1 8F-FDG-PET for other reasons. So, these cases demonstrate that diffuse 18F-FDG uptake by bone marrow likely suggests neoplastic disease of the hematopoietic tissue. [44] 18F-FDG-PET has shown efficacy for the detection of bone marrow metastases from several malignancies including lung carcinoma, breast carcinoma, and lymphoma [ 45-49]. It is unclear to which extent lesions are involved in bone marrow and bone metastases. A recent study of 21 patients with diffuse large B-cell lymphoma (DLBCL) and bone marrow involvement, showed that the bone marrow uptake of 18F-FDG depends on the histological type of the cell infiltrate. In this study, 18F-FDG-PET showed abnormal foci of uptake in most patients with concordant bone marrow involvement (prominent diffuse large- B-cell lymphoma) , whereas 18F-FDG uptake was normal in most patients with discordant bone marrow involvement (prominent indolent lymphoma) [50]. Another study demonstrated at initial staging of Hodgkin Lymphoma (HL) that diffuse bone marrow uptake without splenic involvement could be due to HL related bone marrow involvement. However, these observations are more likely to be due to bone marrow inflammatory changes. In contrast , diffuse spleen uptake in combination with bone marrow uptake is probably more associated with disease involvement than with inflammatory changes [51]. Moreover, a report which describes the role of 18F-FDG as a tracer to visualize bone marrow metastases in 257 patients with newly diagnosed lung cancer, the accuracy, sensitivity and specificity of 18F-FDG-PET and bone scintigraphy were 94% vs 85% ,  91  % vs 75%, and 96% vs 95%, respectively [45]. A previous study investigating the bone marrow status in 112 breast cancer patients with NO or Nl disease (who had undergone bone marrow aspiration twice) demonstrated that tumor cells are present in the bone marrow in 83% of the cases at the time of primary surgery. The latter was reduced to 24% ,  12 months after initiation of adjuvant systemic chemotherapy [52]. This supports the concept that systemic treatment is effective in reducing the number of tumor cells within the bone marrow. Further studies are warranted to investigate this differential response to systemic therapy. When metastases are mainly confined to the bone marrow compared to those that involve the bone matrix, this would 
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CHAPTER2 further enhance the role of metabolic imaging of bone marrow metastases by 1 8F-FDG­PET in various malignant disorders. 
1 8F-FDG-PET can also be used for the evaluation of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) [53,54]. Follow-up 1 8F-FDG-PET scans were performed in patients with CML after termination of treatment [ 54]. 1 8F-FDG-PET findings showed reduced 1 8F-FDG uptake in the bone marrow. Also localized relapse of ALL in bone marrow can be visualized with 18F-FDG-PET [53]. 18F-FDG-PET has already been shown to be useful in the initial staging of multiple myeloma (MM) patients (fig. 2). As well, it was demonstrated to be valuable in patients with solitary plasmacytoma in bone as well as in patients suffering from extramedullary plasmacytoma [55]. Somatostatin receptor scintigraphy (SRS) using 1 1 1In-pentetreotide may also be a good alternative to study the presence of the malignant plasma cells in MM and plasmacytoma patient, especially at relapse [56]. 99mTc-sestamibi has also been proposed as a potential tracer in patients with MM [57]. The patterns of 99mTc-sestamibi uptake in patients with MM are related to both the clinical status and the stage of disease. The presence of focal uptake or of intense diffuse bone marrow uptake suggests that the patient has active and advanced stage disease, while a negative scan in a patient with MM clearly indicates remission [57]. Compared with 99mTc-sestamibi 1 8F-FDG-PET-CT performed better in the detection of focal lesions, whereas 99mTc-sestamibi was superior in the visualization of diffuse disease. In the spine and pelvis [58]. Finally, it is evident that 18F-FDG-PET may become useful in the initial staging, follow-up, and restaging of patients with bone marrow malignancy. 32 
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Figure 2: FDG PET in a patient with multiple myeloma. Lesions are visible in the ribs, right scapula en sternum. 
Imaging of the proliferative activity The thymidine analogue 3-deoxy-3- 18F-fluorothymidine ( 1 8F-FLT) has been developed as a PET tracer to image cell proliferation [59]. The pyrimidine analogue thymidine is incorporated in DNA and undergoes the same first metabolic step as thymidine: 
18F-FLT is taken up by the cell by both passive diffusion as well as facilitated transport by Na+-dependent carriers. Subsequently, 18F-FLT is phosphorylated by thymidine kinase 1 (TKl)  into 18F-FLT-monophosphate, after which it is trapped in the cell. The phosphorylation by TKl forms the basis of 18F-FLT as a proliferation tracer. As a result of this behavior, reduced 18F-FLT uptake is seen in the affected area after radiotherapy (fig. 3). Accordingly, increased 18F-FLT uptake in bone marrow and spleen is seen in patients with AML. This uptake was significantly higher in patients with relapsed, refractory, or 33 
CHAPTER2 
untreated leukemia [60]. Therefore, 18F-FLT could be an imaging biomarker of disease 
activity. EMH lesions can also be seen with 18F-FLT-PET (fig. 4E). 
In a pilot study, we recently demonstrated 18F-FLT distribution in hematologic disorders 
[61]. There is increased 18F-FLT uptake in the bone marrow areas compared with healthy 
control subjects and a significant expansion of the bone marrow compartment in patients 
with MDS (fig. 4B). MPDs showed remarkable expansion of bone marrow with high 
uptake (fig. 4C). Despite the large size of liver and spleen in two patients with MPD, 
18F-FLT uptake in these organs was not elevated. Significantly higher uptake in the spleen 
and liver with distinct hepatosplenomegaly was characteristic of MF, with bone marrow 
uptake significantly reduced and expansion may be seen (fig. 4D). 18F-FLT may also be 
a valuable tool to visualize the bone marrow compartment and identifies solitary areas 
of increased proliferative activity that can frequently be recognized in patients with AA 
(fig. 4A). Increased 18F-FLT uptake is demonstrated after stem cell transplantation in a 
group of patients with lymphoma. At the same time there is an extension of bone marrow 
activity in the peripheral skeleton. These findings correlated with in vitro data showing 
a higher proliferative activity of hematopoietic progenitor cells [62]. 18F-FLT-PET may 
be a promising method for non invasive evaluation of bone marrow activity after bone 
marrow transplantation. 
1 1C-methionine is another PET compound that can be used for imaging the amino acid 
activity in highly proliferative tissues, such as bone marrow [63]. The mechanism of 
increased uptake of 1 1C-methionine in bone marrow has been described as an expression 
of increased cellular proliferation and protein synthesis [64]. MM is a process that is 
characterized by neoplastic proliferation of plasma cells, and these cells produce nearly 
always complete monoclonal immunoglobulins or monoclonal immunoglobulin light 
chains. The unrestricted expansion of a plasma cell clone and the excessive synthesis 
of monoclonal immunoglobulins result in extensive skeletal destruction and anemia. 
1 1C-methionine incorporation into immunoglobulins of the malignant plasma cell clone 
in vivo can be assumed. On the basis of increased methionine uptake in plasma cells, 
active MM can be imaged with 1 1C-methionine PET [64]. Nunez et al., compared 
1 1C-methionine with 18F-FDG-PET in 12 metastatic prostate cancer patients. The authors 
reported that 1 1C-methionine PET was more effective than 18F-FDG-PET for detecting 
bone metastases, including bone marrow involvement in this patient population [63]. 
34 
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Figure 3: Normal distribution of 1 8F-FLT PET (A); the effect of radiotherapy on bone marrow activity on 
the 4th lumbar vertebra and mid-thoracic vertebrae (B) .  The potential advantages of PET using radiolabeled phospholipids, such as 1 1C- and 
18F-labeled choline, in the assessment of prostate cancer patients have been emphasized in previous studies [ 65 ,66]. Choline uptake seems to be a marker of cell proliferation in prostate cancer, as malignancies are commonly characterized by increased proliferative activity. The second explanation proposed is upregulation of choline kinase in cancer cells: overexpression of choline kinase has been found in cancer cell lines, including human-derived prostate cancer [67]. Cimitan et al., examined 100 postoperative prostate cancer patients with persistent increased serum PS A levels, suggestive oflocal recurrences or distant metastases. 18F-choline PET-CT correctly detected bone involvement in 21 % of patients; also 76% of them were undergoing hormone therapy [65]. Bone marrow metastases were not scored separately in this study, but 18F-choline may be an interesting PET tracer for this purpose. 
1 1C-acetate has also been used for the imaging of prostate cancer and the genitourinary system during the last few years and shows preferable characteristics for visualizing the pelvis due to its lack of urinary excretion and its acceptable tumor to background contrast 
CHAPTER2 
[68 ,69]. The value of 1 1C-acetate PET in previously published data show that it might 
have significant potential for the detection of recurrences and bone metastases when using 
more advanced PET/CT equipment [70] . Probably 1 1C-acetate may also be an interesting 
PET tracer for evaluation of bone marrow metastases . Recently, 18F-fluoroacetate has 
been introduced as a possible alternative to 1 1C-acetate for PET imaging , especially with 
respect to its longer half-life [7 1]. 
A B D E 
Figure 4: Different bone marrow patterns in l 8F-FLT PET. A) A patient with AA. Several patchy hot lesions 
with increased proliferative activity are visible in the spine and femora, and mainly higher liver uptake 
compared to controls . B) A patient with MDS shows a relatively homogeneous 1 8F-FLT PET pattern in 
the bone marrow of the spine and relative heterogeneous expansion in the extremities, but the extremities 
can also be homogeneous . There is normal uptake in the liver and spleen. C) A patient with MPD shows 
homogeneously increased uptake and extensive peripheral bone marrow expansion into extremity bones 
and no elevated uptake in the liver or (enlarged) spleen. D) A patient with MF shows low uptake in the bone 
marrow compartment. Elevated uptake in the enlarged spleen and moderate elevated uptake in the liver as a 
result of extramedullary haematopoiesis . E) A patient with thoracic paravertebral EMH with �-thalassaemia. 
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Future perspectives and conclusion 
Several patterns of bone marrow uptake can be identified depending on the hematopoietic 
activity, the underlying disorder and the radiopharmaceutical used. The appearance of 
the bone marrow activity can be more or less identical recognized with gamma- or PET 
cameras . However, differences were noted in the resolution and quality, and PET offers the 
ability of SUV quantification of the bone marrow activity. Different targets can be used for 
imaging the total normal and diseased bone marrow compartment. This is an advantage 
compared to a bone marrow biopsy by which 1-2 cm of the bone marrow compartment 
is evaluated. Imaging may help to differentiate in various bone marrow diseases and 
may play a part in monitoring treatment and bone marrow transplantation effect. New 
developments in PET tracers are entering our field of nuclear medicine. Imaging of 
hypoxia and programmed cell death of the bone marrow compartment are two features 
that can be studied in the future for monitoring disease activity or for studying the effects 
of therapy including chemotherapy, kinase inhibitors or radiotherapy [72] . A number of 
agents exploit the low oxygen tension in hypoxic tissues to permit intercellular trapping by 
reductive mechanisms. [18F]Fluoromisonidazole-3-fluoro- 1-(2 °-nitro-1 °-imidazolyl)-2-
propanol ( 18F-MISO) and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone (64Cu-ATSM), 
and the recently introduced [18F]fluoroazomycinarabinoside ( 18F-FAZA) are the lead 
contenders for human application. This promise is based on their non invasive nature, 
ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate 
heterogeneity and general availability [72,73] .  18F-FAZA uptake by normal bone marrow 
cells is relative low, but may potentially increase during hypoxic circumstances [72] . 
Apoptosis or programmed cell death visualized with 18F-annexin AS may be of use to 
study the effectiveness of treatment in leukemia, MM or myeloproliferative disorders 
[74]. 
In future, 18F-lmmuno-PET or labeled with the longer living PET-label 89Zr is of interest 
for the determination of CD66 distribution in the bone marrow especially for the 
evaluation of leukemia [75]. The CD66 antigen is expressed at the cell surface of mature 
myeloid cells including promyelocytes and granulocytes. It is therefore an attractive 
target for the detection of the extent of the monotonous population of leukemic cells 
in the bone marrow and probably also of value to monitor minimal residual disease 
following treatment . Anti-CD66 monoclonal antibodies (mAbs) labeled with beta­
emitting nuclides ( 1 88Re and 90Y) have already been introduced and are suited as part 
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of treatment in high risk leukemia [76]. Neovascularisation is also a prominent feature 
of malignant transformation. Recently different agents have been introduced in the 
clinical practice including monoclonal antibodies against VEGF or kinase inhibitors of 
the VEGF receptor. New imaging tools with 89Zr-bevacizumab have become available 
in solid tumors for visualization of neovascularisation [77]. This might be also an 
attractive approach for hematological disorders since enhanced neovascularisation is 
also a prominent feature in AML [78]. In conclusion, a variety of bone marrow targets 
can be imaged with radionuclide imaging, where PET offers the opportunity of absolute 
quantification of bone marrow activity. Imaging may help to differentiate in various 
bone marrow diseases and can play a role in monitoring treatment effect. 
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Abstract 
Few diagnostic procedures are available to determine the degree of bone marrow 
cellularity and the numbers of cycling cells in patients with bone marrow disorders. 
Non-invasive imaging of the bone marrow compartment may be helpful. The PET tracer 
[ 1 8F]-3 '-fluoro-3 '-deoxy-L-thymidine ( 18F-FLT) has been developed recently. 18F-FLT 
uptake is related to the rate of DNA synthesis and increases with higher proliferation 
rates in many types of cancer. Background uptake of 18F-FLT in bone marrow is common. 
18F-FLT-PET might, therefore, visualise the high cycling activity of haematopoietic 
cells in the bone marrow compartment. Therefore, we investigated the feasibility of 
visualisation and quantification of the activity of the bone marrow compartment with 
18F-FLT-PET to distinguish different haematological disorders. Methods Clinical and 
laboratory data of 18 patients with myelodysplasia (MDS), chronic myeloproliferative 
disorders, myelofibrosis (MF), aplastic anemia (AA) or multiple myeloma (MM) 
were correlated with the results of 18F-FLT-PET imaging using visual analysis and the 
standardized uptake value (SUV). Findings were compared with those of healthy control 
subjects (n=14). Results With SUV and visual analysis a distinction could be made 
between MDS (N=9), chronic myeloproliferative disorders (N=3) and myelofibrosis 
(n=3) compared with healthy control subjects. A significant increase in 18F-FLT uptake 
was observed in all the studied patients with MDS and myeloproliferative disorders. In 
contrast, patients with MF and AA (n=l) demonstrated a decline in bone marrow 18F-FLT 
uptake compared with healthy control subjects. Comparable results were observed in 
osteolytic lesions of patients with MM (n=2). Conclusion 18F-FLT-PET can be used to 
visualize the proliferative activity of the bone marrow compartment and may be helpful 
to distinguish separate haematological disorders. 
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Introduction 
1 8F-FLT-PET IN HAEMATOLOGICAL DISORDERS In the management of patients with a haematological disorder, limited diagnostic procedures are available to determine the degree of bone marrow cellularity and the numbers of cycling cells. Primarily a bone marrow biopsy is performed in conjunction with microscopic evaluation. With these methods the bone marrow composition and cellularity can be analyzed. In addition, specific staining procedures can be performed to demonstrate the number of cycling cells. This procedure has distinct limitations: the procedure is invasive and only a very small proportion of the total bone marrow content is investigated, which carries the risk of sampling error. Also, the staining of the bone marrow cells with the monoclonal antibody Ki67, which reflects the number of cycling cells, is an in vitro procedure [l ] .  This might not always reflect the in vivo situation. Non-invasive imaging of the bone marrow cellularity has been pursued using many tracer methods. Bone marrow scintigraphy can be divided into 3 categories based on the three target cell systems: red cell precursors, white cell precursors, and tracers for the reticuloendothelial system (RES). For example, in the past, 52Fe was used for imaging of the erythropoietic precursor and 59Fe for kinetic studies [2-4]. The exact target of 1 1 1In­chloride, frequently used in the 1970s and 1980s, is unknown [5-6]. Recently, 99mTc­labeled antigranulocyte antibodies have been proposed to assess activity of granulocytic cells [7-9]. Finally, the activity of the RES can be assessed using 99mTc-labeled colloids. Important problems, however, with all of these agents appear to be non-specific co uptake in RES (monocytes, macrophages, and so forth), the formation of human antimonoclonal antibodies or less desirable imaging properties (59Fe and 52Fe). The DNA precursor 3 '-fluoro-3 '-deoxy-L-thymidine ( 18F-FLT) has been developed Recently. Uptake of this tracer is directly related to the rate of DNA synthesis [10]. Preliminary results with this tracer in several types of cancer patients have demonstrated a high 'background' activity in the bone marrow compartment [11]. This might reflect the high cycling activity of haematopoietic cells in the bone marrow. However, the exact mechanism of 18F-FLT uptake in bone marrow is still unclear. In several tumor types a relation between 18F-FLT uptake and the proliferation rate has been found, suggesting that the same mechanism could be responsible for the bone marrow uptake [ 11]. The suggested specificity of 18F-FLT uptake for cycling cells, the whole body imaging aspect, the high resolution of PET, and the quantification possibilities may support the relevance of 18F-FLT-PET as diagnostic procedure in haematological disorders with bone 49 
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marrow abnormalities. These aspects could be of great advantage over 18F-FOG-PET, 
which only has a minor uptake in normal bone marrow and might, therefore , be less 
sensitive. This is the rationale of our study. Patients with myelodysplasia (MOS) , chronic 
myeloproliferative disorders , and myelofibrosis (MF) in conjunction with healthy control 
subjects were studied using the degree of 18F-FLT uptake and the distribution pattern as 
the main study parameters. 
Materials and Methods 
Patients 
Consecutive patients with haematological disorders were eligible for this study. The 
precise diagnosis was derived from clinical information and bone marrow biopsies. 
Patients were divided in 4 groups: MOS, chronic myeloproliferative disorders , MF and 
a miscellaneous group of patients. Patients with severe renal dysfunction , peripheral 
neuropathy, or severe elevation of liver enzymes were excluded. All patients provided 
written informed consent, and the study was approved by the local Medical Ethics 
Committee of the Groningen University Medical Center. 
Controls 
Patients with untreated non-small cell lung cancer (NSCLC) or testicular cancer, who 
had undergone 18F-FLT-PET for other studies , were considered as the control subjects. 
Before inclusion, they were required to have normal blood hematology values , and 
no signs of bone marrow metastases at presentation or during 6 month follow-up. In 
addition the patients had to be free of chemotherapeutic or radiotherapeutic treatment. 
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Table 1: Patient characteristics . 














1 1  
1 2  




1 6  MM 
17  MM 
1 8  AA 
Hb 
18F-FLT-PET IN HAEMATOLOGICAL DISORDERS 
Leuco. Thrombo. 
7.5-9.9 mmol/1 4-10xl09/l 150-0xl09 /I 
7 .2 5 1 6 1  
6.4 8 .7 2 14  
5 .4 1 . 1 108 
7 .8 4.6 89 
6.5 6 .5 2 1 8  
5 .6 9 .4 490 
5 .9 3 .2 199 
6.5 10  68 
5 .3 5 .9 436 
5 .7 20.2 244 
6 .5 4.6 404 
5 .2 1 1 .6 170 
4.1 1 .9 1 1  
7 .2 7 . 1  1 32 
6 . 1  1 6 .9 1 10 
8 .5 4.5 190 
8 .4 4.8 177 
6 .6 1 .9 14 
*RA = refractory anemia, RARS = refractory anemia with ringsideroblasts , RABB = refractory anemia with 
blast excess , CMML = chronic myelo-monocytic leukemia, MM= multiple myeloma, AA = aplastic anemia. 
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T a b l e  2 :  F L T  fi n d i n g s  i n  d i f fe r e n t  b o n e  m a r r o w  d i s o r d e r s .  
P a t i e n t  
V i s u a l  F L T  a s s e s s m e n t  
S U V  F L T  
L i v e r  S 2 l e e n  E x 2 a n s i o n  G e n e r a l  
F e m R  F e m L  C r R  C r L  L 4  
T 6  
L i  S e i n e  S p  
I.>,)  
M y e l o d y s p l a s i a  
1  +  +  5  H o m o g e n e o u s  4 .4 4 .9 3 . 3  3 . 6  5 . 6  7 . 1  2 . 1  7 .3 0 . 8  
2  +  
1 1  H o m o g e n e o u s  
5 . 8  5 . 8  6 . 8  6 . 9  
8 . 6  6 . 6  
1 . 9  8 . 2  
0 . 9  
3  +  
+  1 6  H o m o g e n e o u s ,  h e p a t o s p l e n o m e g a l y  
6 . 8  6 . 8  7 . 8  7 . 6  
1 0 . 2  9 .6 2 . 1  9 . 9  2 . 4  
4  + +  
+  5  H o m o g e n e o u s ,  p a t c h y  e x p a n s i o n  2 . 2  
1 . 6  2 . 4  5 . 2  9 . 2  
6 . 9  
5 . 0  8 . 2  
1 . 3  
5  +  +  1 0  h o m o g e n e o u s  
2 . 7  
2 . 6  5 . 3  5 . 2  5 .2 6 . 6  3 . 2  6 . 2  1 . 5  
6  +  
7  H o m o g e n e o u s  4 . 6  
5 . 8  
5 . 3  7 . 1  
8 . 0  2 . 0  
7 . 8  0 . 8  
7  +  +  2  H o m o g e n e o u s  
8 . 3  
5 . 6  5 . 7  7 . 2  
7 . 5  
1 . 9  8 . 2  1 . 5  
8  +  +  
7  H o m o g e n e o u s  
1 . 8  1 . 5  4 . 1  4 . 3  6 . 9  
8 . 0  
3 . 8  8 . 1  0 . 9  
9  +  
8  H o m o g e n e o u s  3 . 0  3 . 0  4 . 3  3 .9 5 . 7  6 . 6  2 . 2  6 . 5  1 . 2  
M y e l o p r o l i f  e r a t i v e  
1 0  +  +  2 2  H o m o g e n e o u s ,  h e e a t o s p l e n o m e g a l y  
3 . 8  4 . 0  3 . 3  3 . 2  4 . 0  
3 . 2  1 . 2  4 . 0  
1 . 0  
1 1  +  +  8  H o m o g e n e o u s  4 . 0  4 .4 5 .5 6 . 8  1 0 . 2  8 . 8  2 . 4  8 . 7  1 . 5  
1 2  +  +  2 2  H o m o g e n e o u s ,  h e p a t o s p l e n o m e g a l y  
5 . 1  4 . 9  3 . 7  3 . 7  
5 . 0  4 . 4  
1 . 5  6 . 0  1 . 5  
M y e l o fi b r o s i s  
1 3  + + +  + + +  2 0  
I n h o m o g e n e o u s ,  s p l e n o m e g a l  y  1 . 0  1 . 0  1 . 2  1 . 2  1 . 8  
1 . 6  
4 . 0  2 . 0  8 . 0  
1 4  +++ + + +  3  H o m o g e n e o u s ,  h e p a t o s p l e n o m e g a l y  0 . 9  1 . 0  1 . 3  1 . 4  2 . 3  3 . 1  4 . 0  3 . 4  6 . 2  
1 5  + + +  + + +  1 0  H o m o g e n e o u s ,  h e p a t o s p l e n o m e g a l y  2 . 7  2 . 3  
1 . 4  1 . 1  
3 . 3  3 .3 3 . 8  3 . 2  4 . 0  
M i s c e l l a n e o u s  
1 6  +  +  0  H o m o g e n e o u s ,  MM  s c a p u l a  R  
17  +  0  H o m o g e n e o u s ,  MM  c r i s t a  
1 8  +++ +  1  H o m o g e n e o u s  0 . 5  0 . 5  
0 . 8  1 . 8  1 . 7  
2 . 8  
4 . 6  3 . 1  
1 . 1  
* F e m R = r i g h t  f e m u r  ,  F e m L = l e f t  f e m u r ,  C r = c r i s t a ,  L 4 = l u m b a r  4  v e r t e b r a l  b o d y ,  T 6 =  t h o r a c i c  6  v e r t e b r a l  b o d y ,  S p l = s p l e e n ,  L i v = l i v e r ,  MM  =  m u l t i p l e  m y e l o m a .  
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Table 3: Mean uptake values of 18F-FLT in various patient groups and healthy control subjects . 
























Bone marrow examination 
Bone marrow biopsy was performed on all patients before 18F-FLT-PET, with a maximal 
interval of one month and a minimal interval of 2 weeks. Cellular proliferation was 
determined in a subgroup using Ki-67 immunostaining with MIB-1 (Ki-67 index) in a 
selected number of patients [ 12]. 
18F-FLT-PET 
18F-FLT was produced according to the method described by Grierson et al with a 
radiochemical purity of >95% and a specific activity of > 10 TBq/mmol [13]. Patients 
were instructed to fast at least six hours before investigation, with the exception of free 
access to water and normal medication. 18F-FLT in a dose of 400 MBq (±10%) was 
administered intravenously. 
Approximately 60 minutes after the 18F-FLT injection, the patient was placed in the 
camera and emission scans of 5 minutes per bed position and transmission scans of 
3 minutes per bed position were acquired over ~ 12 bed positions to cover the whole 
body. An ECAT EXACT HR+ scanner (Siemens Medical Systems) was used for all PET 
studies. Images were acquired in the three-dimentional acquisition mode. 
Data analysis 
two nuclear physicians who were unaware of the results of bone marrow biopsy and the 
clinical diagnosis performed visual and quantitative analysis of 18F-FLT-PET images. 
As this is a new application of 1 8F-FLT-PET, the first readings were independent and a 
consensus reading was carried out afterwards. In visual analysis the overall scan pattern 
was recorded, the intensity of bone marrow uptake as well as the degree of bone marrow 
expansion were evaluated. To quantify bone marrow expansion, we developed a simple 
scoring system in which one point is given for expansion in every one third of the long 
bones, based on the well known distribution of 18F-FLT in the central skeleton and ultra­
proximal part of femora and humera. Also the liver and spleen size and uptake intensity 
were evaluated qualitatively: + denotes minor uptake intensity, ++ denotes intermediate 
uptake, +++ denotes strong uptake intensity. 
We also quantified FLT uptake using standard SUV analysis in patients and control 
subjects. We selected several sites of the axial skeleton to sample 18F-FLT activity. These 
sites were the proximal femur (left and right) at the level of the trochanter major, the iliac 
crest on both sides, the corpus of lumbar vertebra 4 and thoracic vertebra 6. In case of 
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1 8F-FLT-PET IN HAEMATOLOGICAL DISORDERS enlargement, also SUV of the liver or spleen was also determined. The region of interests used in SUV analysis were three-dimensional and were based on the mean value within the 50% isocontour's boundaries using a Siemens Leonardo workstation. 
Statistics For analysis of overall and individual group differences, we used Kruskall- Wallis and Mann-Whitney U tests. For correlations, we used Spearman's g. P values < 0.05 were considered significant. 
Results 
Patients Eighteen patients were included in this study, 10 men (mean age 69 y) and 8 women (mean age 64 y). Patients groups included MDS (n=9), according to International Prognosis Scoring System score belonging to the low-risk or low-intermediate risk group [14], chronic myeloproliferative disorders (n=3), MF(n=3) and a miscellaneous group of patients (AA n= 1, MM n=2)(Table 1 and 2). Fourteen untreated patients known with NSCLC or testis carcinoma were used as the control group. None of the patients had bone marrow involvement and none had undergone chemotherapy or radiotherapy and had normal peripheral blood cell counts. 
Visual analysis and SUV of 18F-FLT-PET in controls All healthy control subjects were verified to have a qualitatively normal 18F-FLT scan with homogenous tracer distribution, as known from all previous 18F-FLT studies (Fig. 1) [15-20]. No bone marrow expansion was observed beyond the axial skeleton, and the size of liver and spleen was within the normal range. Within the group of healthy control subjects no difference was observed for 18F-FLT uptake between the right or left uptake from the same area (Table 3). The lowest uptake was observed in the femura (1.41 ± 0 .73) and the highest uptake in the thoracic and lumbar vertebral body (3 .52 ± 1.12; 3 .38 ± 1.05). 
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Visual analysis and SUV of 18F-FLT-PET in patient groups Overall, significant differences were found between the patient groups for all sites of 
18F-FLT uptake (Kruskal-Wallis test, P values between 0.003 - 0.001) and the expansion score (P < 0.0001) (Fig. 2). 
MDS groups Visual analysis in 8 MDS patients demonstrated a homogenous 18F-FLT pattern in the bone marrow (Fig. 3). In one patient 18F-FLT-PET showed a patchy uptake with hot spots distributed over the skeleton. SUV analysis of the total MDS group demonstrated significantly increased 18F-FLT uptake in all of the tested bone marrow areas compared with healthy control subjects (P < 0.001, Table 3). In addition, a significant expansion of the bone marrow compartment was shown (P < 0 .00 l ). Liver and splenic uptake were similar to the 18F-FLT uptake in control subjects. 
Chronic myeloproliferative group 
18F-FLT uptake in these 3 patients was homogenous, with hepatosplenomegaly in two (Fig. 4). As expected, this group of patients had remarkable expansion of bone marrow uptake with a mean expansion score of 17 .3 ± 8 (P < 0 .000 l vs control subjects). This was also higher compared with the MDS group but the difference was not significant. Despite the large size of liver and spleen in two, 18F-FLT uptake in these organs was not elevated. SUV analysis in this small subgroup yielded higher values than those in the control group in the right femur, both iliac crests, and L4 vertebral body. Values were highest in L4 and T6 but no significant difference was observed in comparison with the MDS group. In this patient group, liver and splenic uptake were similar to the uptake in controls. 
Myelofibrosis group 
18F-FLT uptake was homogenous in two patients but was irregular in one patient. Significantly higher uptake in the spleen and liver with distinct hepatosplenomegaly was characteristic of this subgroup compared with healthy control subjects (Liver: 3 .95 ± 0.11 vs 2.33 ± 0.74, P < 0.05; Spleen 6.0 ± 2.2 vs 1.46 ± 0.41) (Fig. 5). Bone marrow expansion was also observed, with a mean expansion score of 6.5 ± 5.0. Expansion was significant in one and moderate in the additional 2 patients. A significant reduced 56 
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18F-FLT uptake was found for left and right crista, and fore the spine (2.87 ± 0 .75 vs 4.56 
± 1.36, P < 0.05). 
Figure 1: Normal 1 8F-FLT PET projection image shows uptake in bone marrow in the central skeletal compartment limited to the ultraproximal extremity bones. 
c::J Controls 
to - MDS t t 9' Myeloprol 
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Location 
Figure 2: Bar graph showing 1 8F-FLT uptake values (SUV mean) at various locations . * P < 0 .05 , t P < 0 .001 for comparison to controls .  Myeloprol = Myeloproliferative disorder; Myelofibr = myelofibrosis .  
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Figure 3 Figure 4 Figure 5 
Figure3: 1 8F-FLT PET in patient with myelodysplasia, shows homogeneously increased uptake and modest peripheral bone marrow expansion into the peripheral bones. 
Figure4: 1 8F-FLT PET in patient with myeloproliferative disorder shows homogeneously increased uptake and extensive peripheral bone marrow expansion into the extremity bones. 
Figures: 1 8F-FLT PET in patient with myelofibrosis shows low uptake in the bone marrow compartment, hepatosplenomegaly with increased uptake as a result of extramedullary hematopoiesis and minor bone marrow expansion into the extremity bones. 
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Miscellaneous group 
1 8F-FLT-PET IN HAEMATOLOGICAL DISORDERS To underscore further that the 18F-FLT uptake is a reflection of the proliferative activity of the bone marrow compartment, one patient with AA was studied. In addition, osteolytic lesions of 2 MM patients were analyzed, as it is known that this malignant plasma cell population has a low proliferative activity. In the patient with AA, a strongly reduced 18F-FLT uptake was observed (Table 2). In the MM patients, the affected area demonstrated a low 18F-FLT uptake. 
Correlations With 18F-FLT uptake parameters 
In the 10 MDS patients Ki-67 staining of the bone marrow was available. No correlation was found between 18F-FLT uptake and Ki-67 positivity. For most locations significant and moderate correlation coefficients (varying between 0.52 and 0.77) between 18F-FLT uptake and the bone marrow expansion scores were found. In addition, a moderate negative correlation of --0.77 was found between 18F-FLT expansion score and hemoglobulin level. 
Discussion This feasibility study appears to confirm the value of 18F-FLT-PET in various haematological bone marrow disorders. Compared with control subjects, bone marrow uptake of 18F-FLT was clearly higher in patients with MDS and myeloproliferative disorders but was lower in patients with MF, MM and AA, in agreement with the cycling activity of the bone marrow compartment of the affected areas. In addition, bone marrow expansion into the peripheral bones was clearly visualized in various degrees in all patients. The combined use of visual analysis and SUV could help distinguish separate haematologic disorders and might be of value for the diagnostic follow-up of this group of patients. In this way, 18F-FLT-PET may provide additional information to data from bone marrow biopsies. 18F-FLT-PET, especially, provides a detailed analysis on the entire bone marrow compartment. 
In MDS, the increased proliferative activity of erythroid and myeloid cells appears to be followed by an increased programmed cell death [21,22] and, as consequences, peripheral pancytopenia. The increased uptake of 18F-FLT in our MDS patients is in agreement with 59 
CHAPTER 3 the high proliferative activity of the progenitor cells in the bone marrow compartment [21]. Although comparable high 18F-FLT SUV values are observed in patients with myeloproliferative disorders, the underlying defects are different. High peripheral blood cell counts are observed frequently in this patient group, which excludes the possibility of increased programmed cell death in the bone marrow compartment. Although in most patients 18F-FLT uptake was homogenous, there was one MDS patient who had a clear patchy 18F-FLT appearance with focal hot spots, possibly indicating 'islands' with high bone marrow activity. In MF, the number of cycling bone marrow cells is reduced due to excessive fibrosis, which is in accordance with the low 18F-FLT uptake. In contrast high SUV values were observed in liver and spleen because of extramedullary hematopoiesis, reflecting proliferative activity of the erythroid and myeloid cells. The mechanisms governing the uptake of 18F-FLT in bone marrow are not fully clarified. In many tumor types, good correlations between proliferative activity and 18F-FLT uptake have been demonstrated [11]. Uptake of 18F-FLT appears to be related to the activity of the thymidine-kinase-1 enzyme, which is expressed higher in tumor cells, especially during the S-phase of the cell cycle [23]. Presumably the same mechanism accounts for the high uptake in the bone marrow compartment with its high proliferative activity. Uptake of 18F-FLT by RES is less likely. This assumption is based on previous studies in both patients and laboratory animals, in which only minor uptake of 18F-FLT in inflammatory lesions was observed [11,24]. However, this assumption needs further validation. No correlation was found with Ki-67 staining. Besides sampling errors, this finding may also be due to the fact that this marker is more suitable to demonstrate a reduced proliferation than an increased proliferation, as normal bone marrow cells already demonstrate high proliferative activity [12]. Studies Comparable as the present study have been performed in the past, using a multitude of tracers, such as iron isotopes for imaging and turnover studies of the erythropoietic precursor [2-4], 99mTc-labeled antigranulocyte antibodies for imaging of myeloid cells [7-9], radiocolloids for RES cell activity, and 1 1 1  In-choride. Compared with those methods, 18F-FLT-PET has a considerably higher resolution, produces tomographic information and allows better quantification. Moreover, it might provide more specific information about the bone marrow compartment than a reflection of the functional activity of the RES . 60 
Conclusion 
18F-FLT-PET IN HAEMATOLOGICAL DISORDERS 
1 8F-FLT-PET provides visual and quantitative information on the entire bone marrow 
compartment studied in a limited number of patients with haematologic disorders. This 
might help in distinguishing various bone marrow disorders and be of value in the 
diagnostic follow-up of these patients. 
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Abstract 
Autologous SCT (auto-SCT) introduces a reduced tolerance to chemotherapy even in 
patients with adequate engraftment, suggesting long-term effects of the transplantation 
procedure on the BM capacity. To study the hematopoietic cell compartment after auto­
SCT, CD34+ BM cells (n=16) from patients at 6-9 months after auto-SCT were studied 
with regard to the progenitor subsets , colony frequency and cell cycle status. The BM 
compartments were studied in vivo using PET tracer 3-fluoro-3-deoxy-Lthymidine 
{ 1 8F-FLT-PET). BM CD34+ cells after auto-SCT were compared with normal CD34+ 
cells and showed a phenotypic shift from common myeloid progenitor (CMP mean 
percentage 3.7 vs 19.4%, P=0.001) to granulocyte-macrophage progenitor (GMP mean 
percentage 51.8 vs 27 .6% , P=0.01). In addition , a reduced clonogenic potential and 
higher cycling activity especially of the GMP fraction (41 %±4 in G2/S phase vs 19%±2, 
P=0.03) were observed in BM after auto-SCT compared with normal. The enhanced 
cycling activity was confirmed in vivo by showing a significantly higher uptake of the 
18F-FLT-PET tracer by the BM compartment . This study shows that auto-SCT results in 
defects of the hematopoietic compartment at least 6 months after auto-SCT, characterized 
by changes in the composition of progenitor subsets and enhanced in vitro and in vivo 
cycling activity. 
AUTO-SCT INDUCES A PHENOTYPIC SHIFf FROM CMP TO GMP PROGENITORS 
Introduction Auto-SCT is a frequently applied treatment modality for patients with multiple myeloma and relapsing lymphoma [1,2]. However, in 30-50% of the patients the underlying malignant disorder relapses within 2-5 years after auto-SCT. Treatment options are then limited not only because of drug resistance of the tumor, but also because of the severe concurrent chemotherapy-induced pancytopenia. Several in vitro studies have shown that the impaired BM capacity might be related to intrinsic defects of the hematopoietic compartment reflected by a reduced clonogenic potential of the long-term culture initiating cells in conjunction with a shortening of telomeres [3-5].After allo-SCT also a higher mitotic activity of BM CD34+/CD90+ cells has been shown [6]. Recent studies in mice and humans have shown that the compartments of the hematopoietic stem cell and progenitor cells (common myeloid progenitor (CMP), granulocyte­macrophage progenitor (GMP) and megakaryocyte-erythroid progenitor (MEP)) can be defined phenotypically with certain surface markers [7 ,8]. These phenotypically defined subpopulations are also verified by in vitro colony assays. In these assays the CMP fraction provided myeloid and erythroid colony formation whereas the GMP fraction generated exclusively myeloid colony formation [9]. In addition, the progenitors and more differentiated hematopoietic cells can be studied in vivo. Recent studies have shown that the cycling activity of the BM compartment can be visualized by using the PET tracer 3-fluoro-3-deoxy-Lthymidine ( 18F-FLT-PET) [10,11]. Distinct patterns of uptake have been shown. In myelodysplasia a significantly higher cycling activity of the BM compartment was noticed whereas in aplastic anemia a significant reduction in cycling activity was shown [10]. Combining both in vitro and in vivo experiments, important information can be obtained regarding the functionality of the hematopoietic stem cell compartment after auto-SCT. The results of this study show that BM CD34+ cells at 6-9 months after auto-SCT show a shift from CMP to a more GMP-enriched phenotype, a reduced colony frequency and a higher cycling activity compared with normal CD34+ cells. These results were validated in vivo by showing a significantly higher uptake of 18F-FLT in the BM compartment after auto-SCT. 
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Materials and Methods 
Patients 
BM samples from patients and normal controls were obtained after informed 
consent according to institutional guide lines. CD34+ cells were isolated by EasySep 
immunomagnetic cell selection (StemCell Technologies, Vancouver, Canada) according 
to manufacture's instructions. 
Flowcytometry analysis and sorting procedures 
Sorting of the CD34+ cells into progenitor fractions was performed on the basis of the 
combinatorial expression of cell surface Ags as previously reported [9]. CMPs were 
defined as CD34+ CD38+CD110+CD45RA+, GMPs as CD34+CD38+ CD110-CD45RA+ 
and MEP as CD34+CD38+CD110+CD45RA-. The FACS analyses were performed on a 
FACS Calibur (Becton Dickinson (BD), Alphen aid Rijn, The Netherlands). Antibodies 
were obtained from BD. Data were analysed using WinList 3D (Verity Software House, 
Topsham, ME, USA) and Flow Jo (Tri Star, Inc, Ashland, OR, USA) software. 
CFC progenitor assays 
The colony forming cell (CFC) assays were performed in 1.2% methylcellulose 
containing 30% PCS, 57.2 µ M  B-mercaptoethanol, and 2 mM Glutamine, supplemented 
with 20 ng/ml IL-3, 20 ng/ml IL-6, 20 ng/ml G-CSF, 20 ng/ml c-Kit ligand and 1 U/ 
ml EPO (Cilag: Eprex; Brussels, Belgium) as previously described [ 12]. To define 
the in vitro cycling activity of the CFC's, CD34+ cells were incubated with variable 
concentrations of cytarabin (Paulding Pharmaceuticals, Brussels, Belgium), that is, 5 x 
I0-6M, 1 x I0-6M, 5 x 10-6M, 7.5 x I0-6M, 1 x I0-5M, 5 x I0-5M, and 1 x 104M during 24 
hrs and subsequently plated in the CFC assay. After 14 days the CFC colony number 
was counted with an inverted microscope. 
Cell cycle analysis 
For cell cycle analysis, Hoechst staining was performed. In brief, cells were resuspended 
at 1 x 106 /mL in warm hematopoietic progenitor growth medium, 5 µ glmL Hoechst 33 
342 (Sigma-Aldrich, Zwijndrecht, The Netherlands) was added and cells were incubated 
at 37°C for 45 min. Medium was removed and cells were stained with antibodies for 
progenitor analysis. Washed cells were kept on ice until FACS analysis. 
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18F-FLT-PET 
18F-FLT was produced with a radiochemical purity of >95% and a specific activity of >10 TBq/mmol. 18F-FLT in a dose of 400 MBq (±10%) was administered intravenously as described [10]. To quantify BM expansion, we developed a simple scoring system in which one point is given for expansion in every one third of the long bones, based on the well known distribution of 18F-FLT in the central skeleton and ultra-proximal part of femoral and humeral bones. The 18F-FLT uptake was also quantified using standard SUV analysis in patients and control subjects. We selected several sites of the axial skeleton to sample 18F-FLT activity. The region of interests used in standarized uptake value analysis were based on the mean value within the 50% isocontour's boundaries using a Siemens Leonardo workstation Forchheim, Germany. The control patients were patients with untreated non-small cell lung cancer or testicular cancer who had undergone 18F-FLT­PET for other studies with normal blood hematology values and had no signs of BM metastases at presentation or during 6 months of follow-up. In addition, the patients were free of chemotherapeutic or radiotherapeutic treatment. The protocols were approved by the institutional medical ethical committee of the University Medical Center Groningen. 
Statistics For analysis of overall and individual group differences, we used Kruskall-Wallis and Mann-Whitney U tests. For correlations , we used Spearman. Differences with a P-value � 0 .05 were considered statistically significant. 
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Table 1: Patient characteristics and peripheral blood cell counts 
Patient Clinical Age Hb Leuco Granulo Trombo 
no diagnosis (yrs) (mmol/l) (xl09/l) (xJ09/[) (xJ09fl) 
MM 62 7 . 1 5 .5 3 .3 1 79 
2 MM 52 7 . 1  5 . 1  2 . 1  2 14 
3 MM 42 8 .4 7 .3 5 .5 147 
4 MM 52 7 .7 3 .4 2 .4 1 1 1  
5 MM 48 8 .3 7 .0 3 .5 2 1 1  
6 MM 62 7 .9 8 . 1  5 .8 2 12  
7 MM 61 7 .6 7 .4 4.5 3 1 2  
8 MM 62 6 .9 6.1 4.2 3 1 8  
9 MM 52 6 .5 9.0 4.5 3 1 3  
1 0  MM 63 6 .7 4.7 2 .3 2 17  
1 1  MM 52 7 .3 5 .8 2 .9 1 70 
1 2  NHL 59 8 . 1 6 .7 4.7 199 
1 3  NHL 59 7 .7 4.3 2 . 15  1 26 
14 MH 50 7 .2 15 1 1 .4 276 
1 5  NHL 48 8 . 1 6.4 4.0 80 
1 6  NHL 46 8 .7 10 . 1  7 .6 1 54 MM: Multiple Myeloma; NHL: Non Hodgkin Lymphoma; MH: M. Hodgkin; Hb: haemoglobulin (n: 7 .5-9 .9 mmol/1); Leuco: leucocytes (n: 4.0- 10 .0x109/l) ; Granulo: granulocytes (n: 2 . 1 -7 .5x109/l) ; Trombo: trombocytes (n: 1 50-400x l 09/l); in vitro colony formation (CFC) assays or 1 8F-FLT-Pet were performed (+) or not (-) .  
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Results 
Patients 
This study included patients with relapsing lymphoma (n=5) treated with intensive 
chemotherapy and auto-SCT using BEAM as conditioning regimen, and MM patients 
(n=l l )  treated with chemotherapy and auto-SCT using high dose melphalan (200 mg/m2) 
as conditioning regimen. The infused auto-SCT consisted of at least 4 x 106 CD34+ cells/ 
kg (range 4.3-12.3 x 106) with only three patients receiving <5 x 106 CD34+ cells/kg. The 
studied patients were analyzed at 6-9 months following auto-SCT. The peripheral blood 
cells counts showed a mean Hb level of 7 .6 mmol/ L (range 6.5-8 .7), a mean leucocytes 
count of 6.9 x 109/L (3.4-15 x 109/L), a mean granulocyte count of 4.4 x 109/L (2. 1-11.4 x 
109/L) and a mean platelet count of 202 x 109/L (80-318 x 109/L) . Patient characteristics 
are depicted in table 1. BM cytology showed no abnormalities . There was no significant 
difference in age between patients after auto-SCT (median 52 years, range 42-63)) and 
controls (median 48 years, range 29-68) (P=0 . l ) .  
Bone marrow CD34+ progenitor subsets after auto-SCT 
The isolated CD34+ BM cells (n=8) were phenotypically characterized for the percentage 
of CMP, GMP and MEP and compared with the distribution pattern of normal BM 
CD34+ cells (n=7) . No significant difference was observed in the percentage of MEP in 
BM after auto-SCT vs normal controls (mean percentage 4.3%, 95% confidence interval 
(Cl) 2 .1-6.5 vs 2 .6%, 95% CI 0 .8--4.5, P=0.3) . However, a significantly increased 
percentage of phenotypically defined GMP (mean percentage 51.8%, 95% CI 39.6-
64.2 vs 27 .6%, 95% CI 19.6-35.5, P=0 .01) was observed, whereas a reduction in the 
phenotypically defined CMP fraction (mean percentage 3.7% 95% CI 0 .7-6.9 vs 19.4% 
95 % CI 11.3-27 .6, P=0 .001) was shown after auto-SCT. A representative experiment is 
depicted in Figure 1. Comparable results were observed in a limited number of patients 
studied with a follow-up time of 43 years as shown for a patient 10 years after auto­
SCT (Supplementary Figure) . No distinct difference in progenitor subsets was observed 
between multiple myeloma or lymphoma patients . 
To further characterize the CD34+ cell fraction after auto-SCT, progenitor frequency was 
tested using the in vitro CFC assay. A decrease in CFC frequency per 103 plated CD34+ 
cells was shown compared with normal CD34+ BM cells ( 109±52 vs 185±56, P=0 .008) . 
In these CFC assays no significant difference was found in the colony distribution of 
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Figure 1: Shift to a GMP-enriched phenotype in the BM compartment after auto-SCT. Representative FACS 
dot plots showing progenitor subsets of normal BM and BM at 6--9 months after auto-SCT. In BM after 
auto-SCT, the percentage of phenotypically defined GMP was increased, whereas a reduced percentage was 
observed in the CMP fraction. With Hoechst staining a higher cycling activity was observed in the CD34p/ 
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Figure 2: Cell cycle analysis ofCD34p cells of patients after auto-SCT (n¼3) compared with normal CD34p 
BM cells (n¼3). Both the total CD34p cell fractions as well as the progenitor subsets (MEP, CMP and GMP) 
were analyzed. BM after auto-SCT showed a significantly higher fraction of cells in S/G2 phase compared 
with normal BM in both the total CD34p and the GMP fraction. Significant differences are marked by an 
asterisk. colony-forming unit granulocyte/monocyte and erythroid burst-forming units in BM after auto-SCT compared with normal BM. In CFC assays from BM after auto-SCT, the percentage of colony-forming unit granulocyte/monocyte colonies was 60.4% (compared with 55 .5% for normal BM, P=0.67) and 39 .1 % for erythroid burst-forming unit colonies (compared with 41 .4% for normal BM, P=0.78) . The decrease in CFC frequency from CD34+ cells after auto-SCT was not due to an impaired proliferative activity. Cell cycle analysis revealed a significantly higher fraction of CD34+ cells in G2/S phase (mean 29%, 95% CI 19 .1-38 .4 vs 14%, 95% CI 1 .6-25 .7, P=0.03) and a reduced percentage of cells in G 1 phase (mean 67%, 95% CI 56.4-78 .2 vs 86%, 95% CI 73 .9-98 .4, P=0.03) compared with normal CD34+ cells (Fig . 2) . It seemed that especially the GMP fraction of CD34+ cells after auto-SCT showed a higher cycling activity (mean percentage 35%, 95% CI 27 .7-43.0 in G2/S phase vs 19%, 95% CI 13.0-25 .7, P=0.03) ,  whereas no significant differences were observed for the MEP and CMP fractions. The higher cycling activity of the GMP fraction was also observed in BM cells of patients with a longer follow-up time. Analysis of the GMP fraction in a patient at 10 years after auto-SCT showed 36 .7% of cells in G2/S phase. To verify whether the progenitor fraction within the CD34+ fraction had an enhanced cycle activity and therefore would be more susceptible to chemotherapy-induced apoptosis, CD34+ cells were incubated in vitro with variable concentrations of Ara-C (range 5x10· 
7 M to 3x1Q-3 M) for 24 h and subsequently cultured in the CFC assay. Normal CD34+ cells showed a 45% reduction in CFC frequency at a concentration of 5x10-5 M (n=4) . Comparable results were observed with CD34+ cells after auto-SCT (n=3) (reduction of 
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39%; NS) . No significant difference was observed in the percentage of CD34+/CD3810w 
cells between patients after auto-SCT and normal controls . However, in the CD34+/ 
CD38 10w fraction also a higher cycling activity was observed after auto-SCT compared 
with normal controls (Fig . I) (P=0 .03) , suggesting that also this fraction is affected by 
the auto-SCT procedure . 18F-FLT-PET scans in patients after auto-SCT 
Recent studies have shown that 18F-FLT-PET scan can be used to visualize the cycling 
activity of the BM by which the degree of uptake is a reflection of the rate of DNA 
synthesis[l0,11] .  The 18F-FLT-PET scans in 10 patients after auto-SCT showed a 
significant increase in standardized uptake values measured at different points of the 
BM compartment (fig. 3) . The mean values of the left and right area were obtained in 
comparison to normal controls: Femur 3.6 ± 0 .7 versus 1 .2 ± 0 .5, P < 0 .001; Crista 3.9 
± 0 .6 versus 2.2 ± 0 .5, P < 0 .001; Lumbar 4 vertebral body 4.9 ± 1 .3 versus 3.1 ± 0 .9, P 
< 0 .005; Thoracic 6 vertebral body 5.0 ± 0 .6 versus 3.2 ± 0 .9, P < 0 .001; Spine 4.7 ± 2 .5 
versus 3.9 ± 0.7 ,  P < 0 .005. Moreover, a significant expansion of the BM compartment 
was noticed (expansion factor of 6 ± 2 .5) . representative 18F-FLT-PET scans of a patient 
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Figure 3: Standard uptake value (SUV) of 1 8F-FLT-scans of normal individuals and patients after auto-SCT. (A) The mean of the left and right SUV was calculated from femur, crista, lumbar 4 vertebral body (IA), thoracic 6 vertebral body (Th6), spine and liver showing a significant increase (P < 0 .005) of SUV for each location in patients after auto-SCT compared with normal individuals .  Significant differences are marked by an asterisk. (B) 18F-FLT-PET scan of a normal individual (a) and of a patient after auto-SCT (b) . 
Discussion This study shows that the auto-SCT procedure results in defects of myeloid progenitors at different levels . BM CD34+ cells after auto-SCT show a phenotypic shift from CMP to GMP progenitors and have a reduced clonogenic potential. Moreover, these cells show an enhanced cycling activity in vitro by 18F-FLT-PET scanning . It is remarkable that even though we observe enhanced proliferation of myeloid cells as determined by 18F-FLT-PET scanning as well as by cell cycle analysis of the GMP fraction, the steady-state peripheral blood cell counts seem to be almost normal at 6-9 months after auto-SCT. Thus, there seems to be an imbalance in the hematopoietic compartment, by which under steady-state conditions the peripheral blood cell counts can be maintained up to normal levels, but at the expense of an increased proliferation rate. Although molecular mechanisms remain to be determined, it is conceivable that cell intrinsic as well as extrinsic factors are contributing to the observed phenotypes after auto-SCT. So far, no enhanced apoptosis was observed in BM cells after auto­SCT as determined by EM studies (E Vellenga, 2009 unpublished data) . Several studies have shown an enhanced decline of telomere length after auto-SCT predominantly of the myeloid lineage [5 ,13] . In aging telomerase knockout mice, enhanced proliferation and cycling activity of myeloid progenitors have been shown in conjunction with a preferential differentiation along the myeloid lineage with a significant increase in the 75 
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GMP fraction [ 14- 16] .  Therefore, chemotherapy application and the auto-SCT procedure 
might have fastened the aging process in patients after auto-SCT, resulting in the shift to 
a GMP phenotype. 
The enhanced cycling activity by CD34+ cells is not restricted to auto-SCT. Patients at 
6-12 months after allo-SCT also have an enhanced cycling activity of the CD34+ cells, 
suggesting that the enhanced cycling activity is not only associated with the exposure of 
DNA-damaging agents [ 6]. It is therefore conceivable that the hematopoietic compartment 
undergoes a replicative stress response because of the infusion and engraftment of a 
limited number of cells. It is of interest whether alternative transplantation strategies 
might improve this situation by increasing the number of hematopoietic stem cells in 
the BM cavity by direct infusion of the SCT in the BM. Indeed studies in mice have 
shown that direct infusion of the stem cell transplant in the BM cavity has advantages 
compared with infusion i.v. [ 17,18]. Comparable results have been shown with cord 
blood transplantation in the setting of allo-SCT [19,20]. Whether this approach will also 
reduce the replicative stress response in the auto-SCT setting requires further study. 
In summary, this study shows that auto-SCT results in defects of the hematopoietic 
compartment after auto-SCT, characterized by a shift to a GMP-enriched phenotype, 
reduced clonogenic potential and enhanced in vitro and in vivo cycling activity. 
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CHAPTER S 
Abstract 
Rationale A discordant relationship between bone marrow cellularity and peripheral blood findings are regular noticed in patients with aplastic anemia (AA). Therefore the feasibility of 3-18F-fluoro-3-deoxy-L-thymidine ( 18F-FLT) 18F-FLT-PET was tested as a non-invasive tool to visualize the total distribution of the hematopoietic bone marrow compartment in AA at presentation or following treatment. Methods In-vivo scanning was performed with 18F-FLT-PET in AA patients (n=l 7) including patients upfront (n= l l) and following treatment (n=6) in addition to peripheral blood cell counts and a bone marrow biopsy. Results A striking abnormal 18F-FLT scan was observed in all patients upfront treatment in particular a reduced uptake of the pelvis was shown, the area that is biopsied for the bone marrow biopsy. Following treatment a number of solitary lesions with increased proliferative activity outside the pelvis was noticed in patients with partial response while patients with a complete remission showed a homogenous uptake throughout the skeleton. Conclusion This pilot study demonstrates that 18F-FLT scan provides a highly distinctive overview of the bone marrow compartment in AA that might be helpful for making a proper diagnosis and treatment response of AA patients. 
Keywords: 18F-FLT, aplastic anemia, bone marrow distribution 
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Introduction Aplastic anemia (AA) is a rare hematological disorder characterized by peripheral pancytopenia in association with a decreased bone marrow cellularity [1]. A number of causative agents have been identified that might be responsible for the bone marrow failure but in the majority of cases no definitive cause can be identified [1]. A bone marrow specimen is a prerequisite for a proper diagnosis of AA. Histological evaluation demonstrates hypocellularity or aplasia with an increased number of fat cells. Moreover, some patients manifest with patchy areas of often aberrant hematopoiesis in the bone marrow specimen called "hot spots" which might be responsible for a discordant relationship between bone marrow cellularity and peripheral blood findings [2,3]. Therefore, a more global investigation of the bone marrow compartment as a whole could be of value for making a proper diagnosis of AA. PET using 18F-labeled DNA precursors has a potential for specific imaging of proliferation in vivo. In the past 3'-deoxy-3'-18F-fluorothymidine ( 18F-FLT) was introduced as a thymidine analog that is resistant to in vivo degradation and accumulates predominantly in proliferating tissues [4]. Results with 18F-FLT in several types of cancer patients have demonstrated a high background activity by the bone marrow compartment reflecting the high proliferative activity of hematopoietic cells [5-7]. This is in line with the enhanced bone marrow 18F-FLT uptake in patients with myelodysplasia and myelofibrosis and patients following autologous stem cell transplantation (8 ,9]. Based on these findings we studied the bone marrow compartment in patients with AA and compared the results with clinical parameters. 
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Materials and methods 
18F-FLT-PET 
18F-FLT was synthesized by the method of Grierson et al [ 10] . 18F-FLT was produced by 
fluorination with 18F-fluoride of the 4,4'-dimethoxytrityl-protected anhydrothymidine 
and then a deprotection step. After purification by reversed-phase high-performance 
liquid chromatography, the product was made isotonic and passed through a 0.22-µm 
filter. 18F-FLT was produced with a radiochemical purity of greater than 95% and a 
specific activity of greater than 10 TBq/mmol. The radiochemical yield was 8.8%± 3.7% 
(decay corrected). 
Patients were instructed to fast at least six hours before investigation , with exception 
of free access to water and usual medication. 18F-FLT in a dose of 400 MBq (±10%) 
was administered intravenously. Approximately 60 minutes after the FLT injection, the 
patient was placed in the camera and emission scans of 5 minutes per bed position and 
transmission scans of 3 minutes per bed position were acquired over ~ 12 bed positions 
in order to cover the whole body. A Siemens ECAT EXACT HR+ (Siemens Medical 
Systems , Knoxville , TN) was used for all PET studies. Images were acquired in the 3-D 
acquisition mode. Three-minute transmission scans with a 68Ge/68Ga ring source were 
obtained for attenuation correction after tracer application. Images were reconstructed 
using an iterative reconstruction algorithm. Emission data were corrected for randoms, 
scatter, and attenuation. 
Controls 
Patients (n=lO) with untreated non-small cell lung cancer (NSCLC) or testicular cancer, 
who had undergone 18F-FLT-PET for other studies , were considered as controls [6-8]. 
Before inclusion , they were required to have normal blood hematology values, lack of 
signs of bone marrow metastases at presentation or during 6 month follow up. In addition 
the patients had to be free of chemotherapeutic or radiotherapeutic treatment. 
Data analysis 
Two independent nuclear physicians prospectively evaluated the PET scans. Visual 
and quantitative analysis of 18F-FLT-PET images was performed. In visual analysis the 
overall scan pattern was recorded, the intensity of bone marrow uptake was evaluated 
as well as the degree of bone marrow expansion. We used the same expansion scoring 
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system which is developed to assess different bone marrow disorders in short: one point 
is given for expansion in every one third of the long bones, based on the well known 
distribution of 18F-FLT in the central skeleton and ultra-proximal part of femora and 
humera [8]. Also the spleen size and uptake intensity was qualitatively evaluated. 
We also counted the lesions in the axial skeleton and quantified 18F-FLT uptake using 
maximal standard uptake value (SUVmax) analysis. Also SUV of the spleen was 
determined . The region of interests using in SUV analysis were three-dimensional 
and based on the mean value within the 50% isocontours boundaries using a Siemens 
Leonardo workstation. Data was expressed as mean ± standard deviation (SD). 
For analysis of group differences, the Mann-Whitney U test was used. P < 0.05 was 
considered significant. 
X)  
T a b l e  1 :  C l i n i c a l  c h a r a c t e r i s t i c s  o f  t h e  s t u d i e d  a p l a s t i c  a n a e m i a  p a t i e n t s  
n  
"'  
P a t i e n t  n o .  
H b  
L e u c o ' s  G r a n u l o c  P l a t e l e t s  B o n e  m a rr o w  
C li n i c a l  d i a g n o s i s  
( m m o l / l )  
( x l 0
9
l l )  ( x l 0
9
/ l )  ( x l 0
9
l l )  h i s t o l o g y  
V,  
1  
T r a n s f .  
1 . 1  0 . 6  
8  A p l a s i a  
A A  
2  
6 . 7  
4 . 6  2  
7  A e l a s i a  
R e l a e s e A A  
3  
5 . 5  
2 . 0  
1 . 0  1 3  
S e v e r e  h y p o c e l l u l a r  
A A  
4  
4 . 9  
3 . 7  
1 . 8  1 1  A e l a s i a  
A A  
5  
6 . 0  
3 . 2  0 . 9  3 2  H y p o c e l l u l a r  
R e l a e s e A A  
6  
T r a n s f .  
4 . 2  
0 . 8  
9  A p l a s i a  
A A  
7  T r a n s f .  
2 . 4  0 . 4 5  
4  A p l a s i a  
A A  
8  
Tr a n s f .  
4 . 5  1 . 5  4 0  A e l a s i a  
A A  
9  6 . 1  
5 . 8  2 . 7  3 4  H y p o c e l l u l a r  
A A  
1 0  T r a n s f .  
5 . 6  
2 . 4  2 0  A e l a s i a  
A A  
1 1  
T r a n s f .  2 . 4  
0 . 2  2  A p l a s i a  
R e l a e s e A A  
1 2  
8 . 3  
4 . 1  1 . 5  1 8 5  n . d .  
A A ;  P R  fo l l o w i n g  A T G / C S P  
1 3  
7 . 9  
5 . 2  
2 . 6  2 5 8  H y e o - n o r m o c e l l u l a r  
A A ;  P R  fo l l o w i n g  A T G / C S P  
14 5 . 4  5 . 2  
1 . 8  4 0  
H  y p o - n o r m o c e l l u l a r  
A A ;  P R  fo l l o w i n g  AT G / C S P  
1 5  9 . 0  6 . 6  4 . 2  
1 6 1  n . d .  
A A ;  C R  fo l l o w i n g  AT G / C S P  
1 6  8 . 0  4.5 2 . 8  1 6 7  N  o r m o c e l l u l a r  A A ;  C R  fo l l o w i n g  a l l o g e n e i c  S C T  
1 7  
8 . 0  
6 . 4  3 . 9  2 0 1  N o r m o c e l l u l a r  A A ;  C R  fo l l o w i n g  a l l o g e n e i c  S C T  
N o r m a l  8 . 0 - 1 0 . 5  4 . 0 - 1 0 . 0  2 . 0 - 7 . 5  1 5 0 - 3 5 0  
A  p l a s t i c  a n e m i a  ( A A )  p a t i e n t s ;  t r a n s f  . :  t r a n s f u s i o n  d e p e n d e n t ;  AT G :  a n t i - t h y m o c y t e  g l o b u l i n ;  C S P :  c y c l o s p o r i n e ;  C R :  c o m p l e t e  r e m i s s i o n ;  P R :  p a r t i a l  r e m i s s i o n ;  
G r a n u l o c :  g r a n u l o c y t e s ;  S C T :  s t e m  c e l l  t r a n s p l a n t a t i o n  
10 
.J 




5 6 7 8 9 1 0  















Total no of 
lesions 5 1 0  
2 7 1 2  1 5  14  
0 1 7  
9 






No lesions* SUV** 2 4.6 
4 4.6 4.3 
4 5 .4 
7 6.0 5 3 .7 6 2 
0 3 .7 
4 6.5 
4 4.8 
0 2 . 1  
9 6.6 
2 4.8 9 5 . 1  
0 5 . 1  
0 4 
0 4 . 1  
0 3 .7±0.65 Cristae No lesions* SUV** 0 1.8 0 2.9 0 2.0 0 2.2 3 .7 3 3 1 .8 0 3 .5 4 4.3 2 3 .8 0 2 . 1  8 .0 7 .7 0 3 .6 0 3 .5 0 2 .9 0 3 .3 0 3 . 1±0.34 Sternum No lesions* SUV** 3 .6 4 .9 0 2.7 3 .3 5 .3 2.5 0 0 .9 0 3 3 3 .2 6 .2 2 .7 3 5 .0 2 5 .3 2 5 .2 0 4.1  0 2 .8 0 3 .2 0 2.3±0. 1  Spleen 1 .4 1 .4 1 .0 1 .9 1 .9 5 .3 3 1 .7 1 .6 3 1 .9 2.2 1 .6 1 .4 1 .4 1 .8 1 .4 1 .7±0.8 *No lesions: number of lesions identified on the 18F-FLT scan; ** SUV: standard uptake values of the identified hot spot(s) at specific areas . Bold text: reflects the residual hematopoietic activity in the cristae or sternum. Patient number corresponds with patient number from table 1 .  ti � ► z 0 ? z Cl) > a n o 0 Cl) � � � >-3 :;,;, o  >-3 0 � r � ;:s  >-3 :;o z �  � � :j � � N � �  � o  - z  >-3 




j m  n �  
� � � o  




17 patients were included, 11 male and 6 female with a median age of 54 year (range of 
20 - 84 year) . The diagnosis of aplastic anemia was based on peripheral blood cell counts 
and bone marrow biopsy. The patients were studied at presentation (n=8) or relapse (n=3) 
and 6 patients were studied after having achieved a partial or complete normalization 
of peripheral blood cells following therapy with prednisolone, anti-thymocyte globulin 
(ATG) and cyclosporine or after an allogeneic stem cell transplantation (table 1) . None 
of the patients were treated with colony stimulating factors. In 15 patients a bone marrow 
biopsy was performed at the same time that the 1 8F-FLT scan was performed. In patients 
(no . 1-11) with moderate to severe AA at presentation or relapse, the findings of the 
the bone marrow biopsy corresponded with the peripheral blood cell counts: severe 
peripheral pancytopenia in association with aplasia or (severe) hypocellularity of the 
bone marrow biopsy. In patients (no. 12- 1 7) with a partial or complete normalization 
of peripheral blood cell counts following treatment, the bone marrow specimen 
demonstrated hypocellularity to normocellularity in 4 of the 6 patients studied. 
18F-FLT-PET 
In patients with presenting AA a significant abnormal 1 8F-FLT scan was observed. Of 
the studied patients no 7 and 16 are the same patient before and following therapy. In 
all untreated patients a significant reduced uptake of the pelvic area was shown unless a 
hotspot was present, while the vertebral column showed patchy areas that varied between 
2-15 spots, and corresponded with the histological findings in the bone marrow biopsy 
which is taken from this area (table 2, fig. lB) .  The patchy areas showed increased 
uptake (SUVmax 4.3 ± 1 .4) compared to normal controls (3.7 ± 0 .65, P = 0 .021, fig . IA 
and lB) .  Six patients (no. 12-17) were studied following immune suppressive therapy 
or allogeneic stem cell transplantation . Three patients (no.12-14) had a partial response 
(PR) based on the findings of the peripheral blood cell counts and bone marrow histology 
(Fig. 2) . The 1 8F-FLT scan in these patients demonstrated hot spots and increased 
uptake that included the peripheral skeleton . The amount of spots varied between 10-
34. The pelvic area showed normal to high 1 8F-FLT uptake (SUVmax 3.6-8) compared 
to the untreated patients (SUVmax 2 .8 ± 0 .9, P = 0 .05) . The patients in CR showed a 
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homogenous 18F-FLT uptake throughout the skeleton without hot-spots but with a certain 
degree of expansion. In almost all the patients a normal uptake of the spleen was shown. A B 
Figure 1: (A) Normal 18F-FLT distribution in the bone marrow compartment. Central skeletal uptake and limited to the bones of the proximal extremities. (B) 1 8F-FLT in untreated aplastic anemia patient (no 8, table 1) showing several solitary lesions of increased proliferative activity in the central skeleton with extension of the lesions to the proximal extremities. Relative low 1 8F-FLT uptake in the pelvis . 
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Figure 2: A: 1 8F-FLT scan in a patient (no 14) in partial remission following treatment with ATG and cyclosporine. The scan was performed 7 months following this treatment; B: 1 8F-FLT scan in a patient (no 16) in complete remission following treatment with an allogeneic stem cell transplantation by using a reduced intensity conditioning. The scan was performed 4 months following this treatment. 
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Discussion The results of this pilot study demonstrate that 1 8F-FLT can be a helpful tool to visualize the bone marrow compartment and identifies solitary areas of increased proliferative activity that can frequently be recognized in patients with AA. In most patients with active disease no activity of 1 8F-FLT was shown in the pelvis which corresponds with the histological findings in the bone marrow biopsy which is taken from this area. Furthermore it appeared that within the bone marrow compartment certain areas with increased or reduced activity can be recognized in connection with an extension to the long tubular bones of more peripheral areas. These solitary areas of increased proliferative activity probably augment following treatment in patients with PR and might be responsible for the improvements in peripheral blood cell counts. Apparently the impairment of the bone marrow compartment is not a general event but is restricted to certain areas with an increased vulnerability for the noxious agents. This is illustrated in a number of patients where solitary lesions of increased 1 8F-FLT uptake were found in the skull, lower legs and upper arms. In contrast patients in CR following therapy demonstrated a homogenous uptake throughout the skeleton. It is like I y that the defined "hot spots" in the bone marrow biopsy of AA patients are linked to the areas of increased 
1 8F-FLT uptake. However, the 1 8F-FLT scan recognizes only the proliferative activity and is not informative regarding the cell lineages involved. The scans obtained in these patients are highly distinctive from that of patients with myelodysplasia or myelofibrosis or normal controls [7-9]. In myelodysplasia a homogenous elevated 1 8F-FLT uptake of the bone marrow compartment was demonstrated while in myelofibrosis a highly increased uptake of the spleen was seen as result of extramedullary hematopoiesis [8]. Therefore, 1 8F-FLT-PET may be helpful in differentiating between these hematological disorders . The mechanisms governing the uptake of 1 8F-FLT in bone marrow are not fully clarified. In many tumor types, good correlations between proliferative activity and 1 8F-FLT uptake have been demonstrated [9]. 1 8F-FLT acts as a chain terminator and is only marginally incorporated into DNA and therefore not a direct measure of proliferation [ 12]. In vitro studies indicate that 1 8F-FLT uptake is closely related to thymidine kinase 1 activity, as well as to expression of nucleoside transporters in the cellular membrane and reflects S-phase fraction rather than DNA synthesis [13,14]. 
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CHAPTER S Studies comparable to the present study have been performed in the past, using a multitude of tracers , such as iron isotopes for imaging, and turnover studies of the erythropoietic precursor, 99mTc-labeled antigranulocyte antibodies for imaging of myeloid cells [15], radiocolloids for RES cell activity, and 1 1 1ln-choride [15-17]. Compared with those methods, 18F-FLT-PET has a considerably higher resolution, produces tomographic information, and allows better quantification. Moreover, it might provide more specific information about the hematopoietic bone marrow compartment than a reflection of the functional activity of the RES. To our knowledge this is the first 18F-FLT-PET study concerning the evaluation of bone marrow proliferation. In conclusion, this study demonstrates that the 18F-FLT scan is a novel non-invasive tool to visualize the hematopoeitic bone marrow compartment and provides a highly distinctive picture that might be helpful to distinguish AA patients from other hematological bone marrow disorders. In addition it might be helpful to monitor the treatment response in future clinical studies. 
Q') 
18F-FLT-PET: A NON-INVASIVE DIAGNOSTIC TOOL FOR VISUALIZATION THE BONE MARROW 
COMPARTMENT IN PATIENTS WITH APLASTIC ANEMIA 
REFERENCES 
1 .  Young NS, Ca/ado RT, Sc-heinberg P. Current concepts in the pathophysiology and 
treatment of aplastic anemia. Blood. 2006;108:2509-251 9 .  
2 .  Fong TP, Okafor LA, Schmitz TH, Thomas W, Westerman MP. An  evaluation 
of cellularity in various types of bone marrow specimens. Am J of Clin Path. 
1 979;72:812-816 . 
3 .  Kansu E, Erslev Al. Aplastic anaemia with 'hot pockets ' .  Scand J Haematol. 
1 976;1 7:326-334 . 
4 .  Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews 
IM, et al. Imaging proliferation in vivo with [F-18JFLT and positron emission 
tomography. Nat Med. 1 998;4:1334-1336 . 
5. Been LB, Elsinga PH, de Vries J, Cobben DC, Jager PL, Hoekstra HJ et al. Positron 
emission tomography in patients with breast cancer using l BF-39-deoxyf-39-fluoro­
l- thymidine (]BF-FLT): a pilot study. Eur J Surg Oncol. 2006;32:39-43 . 
6 .  van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga 
PH et al. Comparison of J 8F-FLT PET and 18F-FDG-PET in esophageal cancer. J 
Nucl Med. 2005;46:400-404 . 
7. Cobben DC, van der Laan BF, Maas B, Vaalburg W, Suurmeijer Al, Hoekstra HJ et 
al. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG 
PET. J Nucl Med. 2004;45:226-231 . 
8. Agool A, Schot BW, Jager PL, Vellenga E. 18F-FLT PET in hematologic disorders: 
a novel technique to analyze the bone marrow compartment. J of Nucl Med. 
2006;47: 1592-1598. 
9 .  Woolthuis C, Agool A ,  Olthof S, Slart RHJA, Huls G,  W. Smid WM, Schuringa JJ, 
VellengaE. Autologous stem cell transplantation induces a phenotypical shift from 
CMP to GMP progenitors, reduces clonogenic potential and enhances in vitro and 




10. Grierson JR, Shields AF. Radiosynthesis of 39-deoxy-39-[18F]fluorothymidine: 
[18FJFLT for imaging of cellular pro.fileration in vivo. Nucl Med Biol. 2000; 
2 7:143-156 . 
11 . Been LB, Suurmeijer Al, Cobben DC, Jager PL, Hoekstra HJ, Elsinga PH. 18F-FLT­
PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 
2004;31 :1659-1672 .  
12 . Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz IL. Validation of FLT uptake 
as a measure of thymidine kinase-] activity in A549 carcinoma cells. J Nucl Med. 
2002;43 :1210-1217. 
13 . Barthel H, Perumal M, Latigo I, He Q, Brady F, Luthra SK et al. The uptake of 
3 '-deoxy-3 '-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on 
thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging . 2005;32 :257-263 . 
14. Perumal M, Pillai RG, Barthel H, Leyton I, Latigo JR, Forster M et al. Redistribution 
of nucleoside transporters to the cell membrane provides a novel approach for 
imaging thymidylate synthase inhibition by positron emission tomography. Cancer 
Res. 2006;66 :8558-8564. 
15. Jamar F, Field C, Leners N, Ferrant . A .Scintigraphic evaluation of the haemopoietic 
bone marrow using a 99mTc-anti-granulocyte antibody: a validation study with 
52Fe. Br J Haematol. 1 995;90:22-30. 16 .  Chung JK, Yeo J, Lee DS, Park S, Lee MC, Kim BK et al. Bone marrow scintigraphy 
using technetium-99m-antigranulocyte antibody in hematologic disorders.I Nucl 
Med. 1996;37:978-982 . 
17. Horn NL, Bennett LR, Marciano D .  Evaluation of aplastic anemia with indium 
chloride In 111 scanning . Arch Intern Med. 1980;40:1299-1303 . 
OA 
Chapter 6 
Effect of radiotherapy and chemotherapy on bone marrow 
activity: a 18F-FLT-PET study 
Ali Agool1 , Riemer HJA. Slart 1 ,Kristin K. Thorp2, 
Andor W J M. Glaudemans1 , David C .P. Cobben3, Lukas B. Been4, 
Fred R .  Burlage5,Rudi AJ.O. Dierckx1 , Edo Vellenga6, Jennifer L. Holter 
1 Department of Nuclear Medicine and Molecular Imaging, Department of 
5Radiotherapy, 6Department of Hematology, 4Department of Surgery, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands; 3Department of Radiotherapy, University Medical Center Maastricht, The Netherlands, 2Section of Hematology/Oncology, Department of Internal Medicine, University of O�lahoma Health Sciences Center, U.S .A. 
Nuclear Medicine Communications. 2011; 32:17-22 
CHAPTER6 
Abstract 
Radiotherapy and chemotherapy are important treatment modalities for a variety of 
malignant tumor types. During therapy for malignant diseases, often the limitation 
for further therapy is determined by the capability of the bone marrow to withstand 
radiochemotherapeutic effects. Evaluation of hematologic toxicity is commonly 
done with peripheral blood counts, and occasionally, sampling of marrow via a bone 
marrow biopsy. Neither method provides a comprehensive assessment, bone marrow 
biopsy is invasive, and both are subject to sampling variability. 3 '-fluoro-3 '-deoxy-L­
thymidine ( 18F-PET) is a non-invasive method and related to the rate of DNA synthesis 
and visualizes the high cycling activity of hematopoietic cells in the bone marrow 
compartment. In order to prove clinical consistency of marrow function and imaging, we 
investigated populations of patients typically seen in clinical practice, post radiation and 
post chemotherapy. In this feasibility study populations were evaluated on 1) to prove the 
ability of visualization and quantification of the activity of the bone marrow compartment 
with 18F-FLT-PET and 2) to evaluate the effect of radiotherapy and chemotherapy on 
bone marrow activity and the correlation with clinical findings. Methods Bone marrow 
activity in the cervical region of 10 patients with laryngeal carcinoma that received 
a mean total dose of 68 Gy (range 30-41 fractions) was evaluated with 18F-FLT-PET 
before and 6 months after radiotherapy. Whole Body 18F-FLT-PET were assessed in 9 
patients with non-seminomatous testicular germ cell tumors before and 4 months after 
the last chemotherapy consisting of 4 courses of bleomycin, cisplatin, and etoposide. 
Maximal standardized uptake value (SUVmax) was used to quantify FLT uptake in bone 
marrow at standard bone marrow regions. Results A significant decrease in 18F-FLT-PET 
uptake was observed in all of the studied laryngeal carcinoma patients in the cervical 
region after RT of the adjacent bone marrow compartment. Tumor stage and additional 
field of view of RT was inversely related to the FLT uptake in bone marrow. The mean 
18F-FLT SUVmax before RT was 3.0 ± 1.34 and after RT 1.94 ± 0.60 (P= 0.013). The 
mean 18F-FLT SUVmax of the spine (Th5-Th12) regions outside the field of view of RT 
were stable and reproducible and not significantly different (5.56 ± 1.56 versus 5.16 ± 
1.35, P = 0 .16). Chemotherapy did not result in a significant difference of whole body 
SUV max value, with a mean SUVmax of 4.99 ± 1.15 pre-chemo, and a mean SUVmax 
of 5 .28 ± 1.0 post-chemo (P = 0 .21). Laboratory analysis of hematologic parameters 
confirmed repopulation of bone marrow. Conclusion Radiotherapy decreases 18F-FLT 
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EFFECT OF RADIOTHERAPY AND CHEMOTHERAPY ON BONE MARROW ACTIVITY: A 18F-FLT-PET STUDY uptake in bone marrow, but not following chemotherapy. We conclude that 18F-FLT-PET is a potential non-invasive tool that can be used in the assessment of quantification of cellular division in the hematopoetic organ. 
Introduction Hematologic toxicity is often the limiting factor in the use of cytotoxic chemotherapy. The introduction of multi-agent chemotherapy has improved management of a variety of solid and hematologic malignancies. However, chemotherapy may result in depressed bone marrow activity resulting in impaired progenitor blood cell proliferation. Depressed bone marrow reserve hampers the use of further cytotoxic chemotherapy. Although limited radiation rarely causes significant impact on marrow capacity, when directed regionally toward highly active marrow sites systemic marrow activity can be affected. Currently, marrow activity is evaluated systemically utilizing peripheral blood counts, and occasionally bone marrow biopsies. Although useful as indirect methods of systemic marrow capacity, both are limited by high of rates sampling errors and accuracy is dependent on limited systemic inflammatory changes. Although MRI and 18F-FDG­PET can provide information about marrow content, they are non-specific and often confounded by inflammatory changes in the marrow. For this reason, a tool that could objectively assess the bone marrow compartment that is both clinically consistent and reproducible would be useful. The PET tracer 3'-fluoro-3'-deoxy-L-thymidine ( 18F-FLT­PET), by its incorporation into DNA during S phase, shows increased uptake in highly proliferative tissues. It is currently being evaluated for tumor staging in a multitude of malignancies (Table 1). 
18F-FLT-PET has been used in several studies to visualize the cellular proliferative rate of the bone marrow compartment [1-3]. In several bone marrow disorders a relation between 18F-FLT-PET uptake and the proliferation rate has been found, suggesting that the same mechanism could be responsible for the bone marrow uptake [29]. The specificity with 18F-FLT-PET uptake for cycling cells, the ability to assess the entire hematopoietic compartment, the high resolution of PET, and the quantification possibilities may support the relevance of 18F-FLT-PET as a diagnostic procedure. In this investigation, we have evaluated two populations where we can objectively evaluate the use of common toxic insults on marrow capacity, namely radiation and chemotherapy. Therefore, we studied in 
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this feasibility study the effect of regional radiotherapy (RT) and systemic chemotherapy 
on bone marrow activity in patients with laryngeal carcinoma and non-seminomatous 
testicular germ cell tumors , respectively, with 18F-FLT-PET. 
Table 1. Evaluation of malignancy with 1 8FLT -PET Imaging 
References Tumor type N Comment 
[ 1 -5] Malignant 1 15 Useful for imaging high grade lesions and predicting 
Glioma treatment response 
[6-8] Colorectal 37 Low sensitivity, especially for liver metastasis . Not useful 
for assessing response to treatment. 
[9- 1 1 ] Non-Hodgkin's 63 Useful for both staging and assessing treatment response . 
Lymphoma 
[1 2-14] Breast 41 Useful for staging ,  with some limitations in sensitivity. 
Useful for predicting response to treatment. 
[ 1 5 ,16] Head/neck 3 1  Sensitivity high , but poor specificity. Not useful. 
[ 17 ,1 8] Sarcoma 29 Useful for imaging both primary tumors and metastatic 
disease. SUV correlates well with mitotic index . Predicts 
response to therapy. 
[ 1 1 ,  19-24] Lung 92 Low sensitivity but high specificity, perhaps useful as an 
adjunct to FDG-PET. 
[25] Esophageal 10 Low sensitivity and high specificity, limited usefulness . 
[26] Melanoma 10 Reasonably useful in tumor staging. 
[27 ,28] Acute Leukemia 16 May be useful in predicting response to therapy 
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Materials and methods Patients 
Patients with laryngeal carcinoma and non-seminomatous testicular germ cell tumors 
that visited the hospital between 2002 and 2005 were retrospectively included for this 
study. Patients with severe renal dysfunction, peripheral neuropathy, severe elevation 
of liver enzymes and metastasized disease were excluded. All patients provided written 
informed consent, and the study was approved by the local Medical Ethics Committee 
of the Groningen University Medical Center. 
18F-FLT-PET 
18F-FLT-PET was produced according to the method described by Grierson et al . with 
a radiochemical purity of >95% and a specific activity of >lO TBq/mmol [31] .  Patients 
were instructed to fast for at least 6 h before investigation, with the exception of free 
access to water and normal medication . 18F-FLT-PET in a dose of 400 MBq (±10%) 
was administered intravenously. Approximately 60 min after the 18F-FLT injection, the 
patient was placed in the camera, and emission scans of 5 min per bed position and 
transmission scans of 3 min per bed position were acquired over 12 bed positions to 
cover the whole body. An ECAT EXACT HR+scanner (Siemens Medical Systems) was 
used for all PET studies . Images were acquired in the 3-dimensional acquisition mode . 
All 18F-FLT-PET scans were fused with the planning CT scans of the RT on Leonardo 
Siemens workstation (Siemens Medical Systems) for delineation of the vertebrae. Radiotherapy 
10 patients (all men, mean age 68 . 1  ± 9.4 yr) with laryngeal carcinoma underwent a 
18F-FLT-PET for tumor activity assessment before and one month after finishing RT 
at a dose of 70 Gy (range 30-41 fractions) . None of the patients had bone marrow 
involvement and none had undergone chemotherapy or radiotherapy in the past and all 
had normal peripheral blood cell counts prior to the therapy. The tumor classification of 
the laryngeal carcinoma ranged from Tl to T4 (table 1) .  
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Chemotherapy 
9 patients (mean age 27.4 ± 5 .3 yr) with metastatic non-seminomatous testicular germ 
cell tumor were treated with 4 courses of chemotherapy (with bleomycin , cisplatin , and 
etoposide). These patients underwent a 18F-FLT-PET for tumor activity assessment one 
week before and 6 months after finishing chemotherapy. None of the patients had bone 
marrow involvement and none had undergone chemotherapy or radiotherapy in the past. 
All had normal peripheral blood cell counts prior to the therapy and after therapy. 
Table 2: Stage, radiation dose and site of radiation in patients with pre-and post irradiation FLT measurements . 
Patient TNM RT dose Number of RT cervical SUVmax SUVmax 
classification (Gy) fractions spine level pre RT post RT T2NOMO 70 35 CI-C7 2.9 1  1 .20 
2 TINOMO 64 41 C2-C6 2.87 1 .59 
3 T4NOMO 70 35 CI-C4 1 .36 1 .57 
4 T2NOMO 70 35 C4-C6 4 . 16 2 .73 
5 TlbNOMO 66 33 C4-C6 3 .8 1  2 .55 
6 T2NOMO 70 35 C4-C7 2.39 1 .84 
7 T2NOMO 70 35 C4-C7 1 .56 1 .2 1  
8 T3NOMO 60 30 C3-C6 1 .56 1 .64 
9 T2NOMO 68 34 C2-C5 5 .40 2 .80 
10  T2NOMO 70 35 C3-C6 4.15 2 .27 Mean±SD 67 .8±3 .4 2.89±1 .28 1 .94±0.60 
RT: Radiotherpy; Gy: Gray; SUVmax: standardized uptake value maximum. 
Data A.nalysis 
We quantified 18F-FLT-PET uptake using the maximal standardized uptake value 
(SUVmax) analysis in all patients. The region of interests used in SUV analysis were 
3-dimensional and were based on the mean value within the 50% isocontour's boundaries 
using a Siemens Leonardo workstation. Regional mean SUVmax was calculated for 
cervical (level 1-7) , thoracic (level 1-12) and lumbar vertebrae (level 1-5) , sternum, and 
pelvis ( crista iliaca both sides). Bone marrow in the field of view of RT in the cervical 
spine region was determined from the planings CT. The meanSUVmax of the thoracic 
vertebrae (level 5-12) in RT patients were used as control. Liver and spleen were also 
analysed using SUV max. As previous expansion into appendicular skeleton was noted in 
patients with myelodysplasia, a known complication of chemoradiotherapy, expansion 
to the appendicular skeleton was analyzed visually. 
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Pre-RT post-RT pre-control post-control 
Figure 1: Figure 1 :  Mean 1 8FLT-PET SUV max value of the cervical bone marrow area before (black bar) 
and after radiotherapy (horizontal lined bar), and mean 1 8FLT -PET SUV max value of bone marrow outside 
the field of radiotherapy (thoracic spine) before (solid grey bar) and after radiotherapy (vertical lined bar) . 101 
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A B 
Figure 2: Images represent pre-radiation (panel A) and post radiation (panel B) 18F-FLT studies in cervical 
bone marrow region after receiving 68Gy for laryngeal carcinoma 
A B 
Figure 3: Images represent pre-therapy(panel A) and post-therapy(panel B) in representative patient 
undergoing chemotherapy for non-seminomatous testicular germ cell carcinoma with no significant 
difference in 1 8F-FLT uptake. 
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Results 
18F-FLT-PET 
No bone marrow expansion was observed beyond the axial skeleton. The size and uptake 
of the liver and spleen was within the normal range. 
Radiotherapy patients 
A significant decrease in 18F-FLT-PET uptake was observed in all of the studied 
laryngeal carcinoma patients in the cervical region after RT of adjacent bone marrow 
compartment. Tumor stage and additional field of view of RT was inversely related to the 
18F-FLT uptake in bone marrow. The mean 18F-FLT-PET SUVmax before RT was 3.0 ± 
1.34 and after RT 1.94 ± 0.60 (P = 0.013) The mean 18F-FLT-PET SUVmax of the spine 
(Th5-Th12) regions outside the field of view of RT were stable and reproducible and 
not significantly different (5.56 ± 1.56 versus 5.16 ± 1.35, P = 0.16, fig. 1). All patients 
had normal peripheral blood cell counts prior to the therapy and remained stable after 
RT (pre-RT: mean value white blood cells (WBC) 6.74 ± 2.91 10e9/L, hemaglobin (Hb) 
8.82 ± 0.57 mmol/L, platelets (plat)269 ± 103 10e9/L; post-RT (< 1 week 18F-FLT-PET 
scanning) : WBC 5.44 ±1.88 10e9/L, Hb 8.14 ± 0.99 mmol/L, platelets 212 ±77 10e9/L). 
Figure 2 shows representative images of pre and post radiation images. 
Chemotherapy patients 
Chemotherapy did not result in a significant difference of SUVmax value, with a mean 




Table 3: Stage, hematologic paramaters , and 1 8F-FLT uptake in pretreatment and post therapy patients with non-seminomatous testicular germ cell carcinoma treated with bleomycin , etoposide and platinum therapy. 
Patient Stage SUVmax Hb WBC Plat SUVmax Hb WBC Plat 
pre chemo post chemo 
1 II 6.87 9 .7 5 .3 162 4.88 8 .3 4.9 141  
2 II 4.16 9 . 1  6 .2 1 5 1  3 .90 8 .7 5 .3 1 29 
3 II 4.06 9.0 9 .3 210 4.95 7 . 1  3 .4 2 15  
4 II 5 .43 9 .7 7 .2 259 6 .6 1  7 .4 2 .8 256 
5 IV 4.82 8 .4 3 .6 210 5 .97 9 .0 4 . 1  232 
6 II 5 .47 9 . 1  5 .3 257 6 .0 1  7 .8 3 .8 1 77 
7 II 5 .47 9.0 6.8 176 4.7 1  5 .7 4.0 1 28 
8 II 6.49 8 .6 7 .5 334 6 .4 1  7 .2 7 .9 484 
9 II 3 .79 10 .2 5 .5 304 4 . 10 8 .3 6 .3 220 
Mean 4.99 9 .20 6 .30 229 5 .28 7 .72 4.72 220 
±SD ±1 . 1 5  ±0.57 ± 1 .63 ±63 ±1 .0 ±1 .0 ± 1 .58 ±109 Hb: Hemaglobin; WBC: total white blood count; Plat: platelets; chemo: chemotherapy. 
Discussion The ability to quantify the effect of radiation therapy on cellular division within the bone marrow compartment is an important initial step in advancing our understanding of bone marrow kinetics. 18F-FLT-PET has already been used in a few patients [27,29] to study acute leukemia and other hematologic disorders. However, 18F-FLT-PET has not yet been used to visualize the effect of therapy-related bone marrow toxicity in patients being treated for malignancy. This feasibility study provides evidence that we can quantify and visualize the amount of hematologic toxicity the patient will be subjected to with a given therapy. Our data indicate that radiation therapy with a mean dose of 68 Gy does diminish 
18F-FLT-PET uptake in the cervical region that may represent reduced hematopoeitic activity. Data show that the chemotherapeutic effect on bone marrow capacity is stable, and 18F-FLT-PET measurements do not change from pre-chemotherapy assessment. The stability of marrow compartment assessment allows for greater use of 18F-FLT-PET as an objective measure of bone marrow capacity over time. In addition, the absence of expansion following chemotherapy can distinguish post-chemotherapy 18F-FLT uptake from myelodysplasia expansion decribed previously [29]. As myelodysplasia is a complication of chemoradiotherapy, this could clinically allow for prediction of early 104 
EFFECT OF RADIOTHERAPY AND CHEMOTHERAPY ON BONE MARROW ACTIVITY: A 1 8F-FLT-PET STUDY risk for treatment associated myelodysplasia, which is often fatal. It is entirely possible that 18F-FLT-PET could be used as a technique to monitor hematopoietic reserve over the course of the patient's chemotherapy. A noted decrease in activity after repeated courses of chemotherapy may represent a diminished number of cycling progenitor stem cells, that might prompt earlier referral for stem cell collection in cases of disease in which bone marrow transplant is a treatment option. 18F-FLT-PET may be a quantitative and descriptive tool for evaluation of the bone marrow capacity during chemo- and/or radiotherapeutic treatment. 
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A 40-year-old Caucasian male known with a history of hemoglobin-E �-thalassemia 
was presented to our department with progressive back pain referred to the both 
limbs, disturbed sensibility and weakness. Due to persisting physical complains a 
MRI of the thorax was performed (Fig. lA), showing a bilateral paravertebral mass. 
The combination of the mass configuration and a patient with �-thalassemia makes 
the presence of extramedullary hematopoiesis (EMH) high ranking in the differential 
diagnosis, but malignant lymphoma could not be excluded. 3'- 18F-fluoro-3'-deoxy-L­
thymidine ( 18F-FLT) is used to detect and assess the hematopoietic bone marrow activity 
and could be helpful for the diagnosis of EMH [1]. 18F-FLT-PET demonstrated bone 
marrow expansion to the distal parts of the skeleton, with a homogeneous activity, 
and an elevated standardized uptake value (SUVmax of spine 4.2; normal 3.7) in bone 
marrow, but decreased in liver and spleen compared to normal values [ 1] .  Normally 
no 1 8F-FLT activity is shown in the distal bones [1]. More importantly, 1 8F-FLT-PET 
revealed multiple EMH masses bilateral and paravertebral in the thorax with an elevated 
SUV max of 5 (Fig. 2). For optimal delineation of the EMH mass 18F-FLT-PET was fused 
with a MRI and demonstrated intense 1 8F-FLT uptake paravertebral in the thorax (Fig. 
lB). Due to the observed findings a new bone marrow aspiration was performed and 
revealed hypercellularity with erythroid hyperplasia as result of a persisting anemia. 
Patient was treated with blood transfusions and hydroxyuria and showed a considerable 
relief of his complaints. 
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Figure 1: A: MRI thorax with a mass paravertebral, B :  Fused 18F-FLT-PET-MRI shows an elevated 18F-FLT 
uptake paravertebral due to extramedullary hematopoiesis. 




Discussion Extramedullary hematopoiesis is a rare disorder and defined as the localization and probably production of myeloid and erythroid cells outside of the bone-marrow cavity. It can be a mechanism to compensate for impaired red cell production or accelatered destruction as in haemolytic anaemia such as spherocytosis or thalassaemia. Alternatively it is shown in response to bone-marrow dysfunction seen in disorders as myelofibrosis or leukaemia [2] . Approximately 5% of the cases with EMH occur outside of the liver and spleen . Of these, the most common sites are surrounding the vertebral column (especially the thoracic region) , lymph nodes, retroperitoneum, lung and pleura [2] . A CT-scan is a common preliminary investigation to demonstrate EMH. It usually appears as heterogeneous lobulated solid mass with smooth margins . Based on CT imaging, the differential diagnosis is lymphoma, which tends to produce a pattern of retroperitoneal involvement oflymph nodes surrounding the great vessels [3 ,4] . An alternative diagnostic tool might be an MRI that often reveals a characteristic well encapsulated tumour with a slightly higher signal intensity than muscle and adjacent marrow of the vertebral bodies on T 1 and T2 weighted imaging [ 5] . The 18F-FDG-PET scan may also reveal mild to moderate FDG activity in multiple paraspinal thoracic masses, just as l l lJn-chloride, 99mTc-colloid, 201Thallium, and 99mTc­sestamibi scintigraphy [ 6-8] , but the SUV value of FDG is in general lower than detected in aggressive lymphoma. 18F-FLT is recently developed to image more specifically the cellular proliferation of different tumours. In particular it can also assess the function and expansion of the hematopoietic bone marrow compartment and shows significant high tracer uptake on PET imaging [1]  of the central skeleton . The pyrimidine analogue thymidine is incorporated in DNA and undergoes the same first metabolic step as thymidine, thus , its uptake reflects the DNA synthesis of the affected tissue. Besides being non invasive, PET imaging permits the evaluation of the entire bone marrow compartment overcoming issues of heterogeneity and bone marrow sampling. In our case EMH was differentiated from malignant lymphoma in a patient that presented large thoracic masses with a familiar red cell disorder. 18F-FLT uptake revealed EMH activity indicating that 18F-FLT-PET is an attractive non-invasive technique for the diagnosis of EMH. 1 14 
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ABSTRACT 
Somatostatin receptor expression has been demonstrated on a number of plasma cell 
lines. Therefore , we questioned whether somatostatin receptor scintigraphy (SRS) can 
be used to demonstrate in vivo multiple myeloma (MM) activity. Methods SRS was 
performed in newly diagnosed (n=9) or relapsing (n=18) MM patients or in patients with 
plasmacytoma (n=2). The results were compared with radiographic findings. Results A 
positive SRS was demonstrated in 44% of the newly diagnosed patients ,  in 83% of the 
relapsed patients and in both patients with plasmacytoma. The SRS findings corresponded 
with radiographic abnormalities in 40% of the patients. However, in relapsed patients 60% 
demonstrated increased SRS uptake in areas without new radiographic abnormalities. 
The positive SRS corresponded with histological proven disease activity and responded 
upon treatment. Moreover, immunohistochemical staining of MM material demonstrated 
concordant somatostatin receptor-sst3 staining in five of six patients. Conclusion These 
results demonstrate that SRS is a valuable tool to detect disease activity, especially in 
relapsing MM patients. 
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INTRODUCTION 
Multiple Myeloma (MM) is clonal B cell disorder characterized by a monoclonal plasma 
cell population in bone marrow, with bone pain as result of skeleton abnormalities, 
hypercalceamia, and kidney dysfunction [ 1]. In a minority of the patients the disorder 
is localized and presents as a solitary plasmacytoma. In 60%-70% of the patients 
skeletal abnormalities are identified by X-ray examination and are characterized by 
typical osteolytic defects [ l ]. Following treatment with chemotherapy or radiotherapy 
the osteolytic defects persist and no clear distinction can be made whether vital tumor 
cells are present in these lesions. Also in relapsing disease the X-ray examination has a 
limited value unless progressive defects are observed. Therefore, it would be attractive 
to have scanning methods that identify the metabolic activity of the malignant plasma 
cells. Previous studies have shown that 18F-FDG-PET might identify the metabolic 
activity of the malignant plasma cells. Several small studies have demonstrated that in 
a high percentage of newly diagnosed MM patients osteolytic lesions are 18F-FDG-PET 
positive due to their higher metabolic activity [2,3]. An alternative approach would be 
the use of tracers that identify tumor-specific receptors. In vitro studies with plasma 
cell lines have shown that the somatostatin receptor is expressed on malignant plasma 
cells. It wsa shown that all MM cell lines express functional somatostatin receptors (sst) 
and that the subtypes sst2, sst3 are predominantly sst5 were present [4]. It is therefore 
conceivable that somatostatin receptor scintigraphy (SRS) using 1 1 1In-pentetreotide may 
be a good alternative to study the presence of the malignant plasma cells [5]. So far 
SRS have been used for the detection of neuroendocrine tumors (NETs) and aggressive 
malignant lymphoma especially to define the extent of the disease [6,7]. Based on these 
findings we performed SRS in patients with MM or plasmacytoma to determine whether 
SRS can be used as an alternative method to detect disease activity in malignant plasma 
cell disorders. 
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Materials and methods 
Patients 
A total of 29 patients were prospectively included in this study (table 1). The patient 
group consisted of 22 men and 7 women with a median age of 59 year (range: 40-85 
year). MM or plasmacytoma was based on the presence of a monoclonal plasma cell 
population in the bone marrow biopsy, the presence of a monoclonal lg protein or free 
light chains (FLC) in serum according to international defined guidelines [1]. 
In all patients total whole-body radiography was performed. In a selected number of 
patients an additional CT-scan or MRI scan was performed based on clinical symptoms. 
Patients were treated according to ongoing trials for MM patients younger than 65 years 
or with melphalan/prednisolon [8-1 O]. Patients ( < 65 years) were treated upfront with 
three cycles of VAD (vincristine, doxorubicin, dexamethasone) or TAD (thalidomide, 
doxorubicin, dexamethasone) . This was followed by peripheral blood stem collection 
following high-dose cyclophosphamide plus granulocyte colony stimulation factor. 
Finally autologous stem cell transplantation was performed with high dose melphalan 
and re-infusion of autologous stem cell. The protocol was approved by the Medical 
Ethical Committee Groningen, The Netherlands and informed consent was obtained 
from all patients. 
Immunohistochemistry 
Bone marrow biopsy or material of extra-osseous localization of MM patients was used 
for these investigations. In two cases the localization was based on a positive SRS. Tissue 
specimens were fixed in phosphate-buffered formaldehyde ( 12-24 h) and decalcified 
using a mixture of 10% acetic acid and 4% formaldehyde (24-48 h). After standard tissue 
processing biopsies were embedded in paraffin wax. Four-micrometer sections were 
cut and floated onto 3-aminopropylethoxysilane (APES)-coated slides. After dewaxing 
slides were microwaved in 10 mmol/1 citrate buffer, pH 6.0, for 15 min at 750 W, 
allowed to cool to room temperature and washed three times in triethanolaminebuffered 
saline. The slides were processed using a Techmate Horizon (Dako, Carpinteria, CA, 
USA) slide processor. Affinity purified polyclonal rabbit antisera specifically directed 
against sst2 (NBl00-74537), sst3 (NLS2622) and sst5 (NLS2639) ( 1  µg/ml, Novus 
Biologicals, Littleton, CO, USA) were incubated for 1 h and binding was visualized 
using a streptavidin-biotin complex reagent (StrepABComplex/HRP Duet, Dako, 
1 ?0 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY MIGHT BE USEFUL FOR DETECTING SKELETON ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA AND PLASMACYTOMA 
Carpinteria, CA, USA). Chromogenic substrate was 3,3'-diaminobenzidine. Slides were 
counterstained with haematoxylin. Positive control of immunostaining was assessed by 
immunohistochemistry of normal pancreatic islets. However, on bone marrow trephines, 
satisfactory results were only obtained for the sst3 staining and not for sst2 and sst5. In 
general, if possible all myeloma cells were stained. The intensity of the immunostaining 
of myeloma cells was reported using the following system: 0: no or extremely weak, +: 
moderate and ++: strong. 
Octreotide scintigraphy 
Whole body scan SRS was performed 24 hours after intravenously injection of 200 MBq 
1 1 1In-pentetreotide. A Multispect 2 Siemens double headed gamma camera (Siemens 
Medical Systems, USA) was used with a matrix of 256x256 and equipped with medium­
energy collimator. Patients were positioned supine on the imaging table; subsequently 6 
views were obtained anterior and posterior of head/neck/thorax, abdomen and the thighs, 
10 min/view. The SRS scan and X-skeleton was performed with a period of 7 days. 
SRS were separately examined by 2 experienced nuclear physicians using visual 
examination with special attention to the skeleton. Any focal tracer accumulation 
exceeding normal regional tracer uptake levels was rated as a pathological. Subsequently, 
regions of interest (ROis) were visually placed over the area with abnormal uptake 
and tracer uptake was quantified by comparing the average counts per pixel of the 
focus in comparison with normal background bone activity assessed from a usually 
symmetrically placed contra lateral background ROI. A simple scoring was developed to 
grade the uptake in the pathological sites. Uptake was recognized as 'slightly elevated' if 
the uptake ratio exceeded 1.5 in the lesion, as 'moderate' when uptake ratio was between 
1.5 and 2, and as 'high' when over 2. Non focal intestinal uptake changing over time 
was considered to be physiological background activity. All scintigraphic results were 
compared with radiographic findings. 
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Table 1: Patient characteristics at presentation or at relapse. 
Patient no Age (yrs) Sex Type of underlying Para-prot. SRS 
disorder 
1 63 f MM IgA-x + 
2 58 f MM IgG-x 
3 54 m MM IgG-11. 
4 57 m MM FLC-x + 
5 62 m MM lgA- x + 
6 53 m MM IgG- x 
7 52 m MM lgG- x + 
8 5 1  m MM IgG-11. 
9 62 m MM IgG- x 
1 0  60 m Plasmacytoma lgA-11. + 
1 1  40 m Plasmacytoma lgG- x + 
1 2  85 m MM-R lgA- X + 
13  56 f MM-R IgG- X + 
1 4  6 1  m MM-R IgG- x 
1 5  64 m MM-R IgG- x + 
1 6  55 m MM-R FLC- x + 
1 7  46 m MM-R FLC- x + 
1 8  48 m MM-R FLC-11. + 
1 9  70 m MM-R FLC- x + 
20 60 m MM-R IgG- x + 
21  63 m MM-R IgG- x + 
22 63 m MM-R IgG- x + 
23 59 m MM-R IgG- x + 
24 67 f MM-R IgG-11. 
25 48 m MM-R FLC- x + 
26 73 m MM-R NS * 
27 65 f MM-R FLC- x + 
28 60 f MM-R FLC-11. + 
29 64 f MM-R NS + *N .S .: non-secretor; FLC: free light chain in serum; MM (R): multiple myeloma (relapse); SRS: somatostatin receptor scintigraphy with a positive ( +) or negative (-)scan 
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Table 2: Somatostatin receptor scintigraphy in multiple myeloma patients upfront treatment or at relapse. 
Patient no SRS Correspondig Whole body radiography 
Whole body 
Scan No of uptake Radiography No lesions No lesions New lytic 
Pos. lesions ratio Abnormalities >lcm <lcm Lesions at 
(yin) Relapse 
>l cm 
2 0 3 y 
3 0 0 N 
4 + 2 y 3 y 
5 + 1 2 .3 Na 0 N 
6 0 1 N 
7 + 2 2 .5 y 0 y 
8 0 0 y 
9 0 0 N 
1 0  + 2 Na 0 N 
1 1  + 1 .5 y 0 N 
1 2  + 1 1  2 ( 1 .5-2 .5) N 0 N 0 
1 3  + 2 2 ( 1 .8-2 .2) N 0 N 0 
14  0 4 y 
1 5  + 2 .5 y 3 N 1 
1 6  + 1 .5 y 6 y 1 
1 7  + 1 2 y 4 y 1 
1 8  + 3 3 (2.8-3 .2) Yb 3 y 3 
1 9  + Diffuse n.a. N 0 y 0 
20 + 1 2  2 ( 1 .5-2 .5) N 3 N 0 
2 1  + 1 1 .3 ya 2 y 1 
22 + 2 y 5 y 1 
23 + 3 2 ( 1 .7-2.2) N 0 N 0 
24 0 0 y 0 
25 + 3 2 N 5 N 0 
26 0 0 N 0 
27 + 2 N 5 y 0 
28 + 3 3 (2.6-3 .3) Nb 3 y 2 
29 + 1 1 .4 Na 0 y 0 
2 0 3 y 
Lytic lesions larger than 1 cm; osteolytic defects present (Y) or absent (N) 
n.a. not available. a No abnormalities on whole body radiography but defects on MRI or CTs-can b Extra ossal localization. 
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Results A total of 27 patients with MM and 2 patients with plasmacytoma were studied. Patient characteristics are presented in table 1. Of the 27 patients with MM, 9 patients had newly diagnosed MM and 18 patients had relapsing disease. MM showed production of IgG-k (n=12) , IgG-1 type (n=3) , IgA-1 type or IgA-k (n=4) types. In eight patients monoclonal FLCs were demonstrated in the serum. Whole body radiography demonstrated abnormalities in 14 of the 29 patients. The type of treatment was dependent on age and whether the patient presented with newly diagnosed or relapsing disease. The newly diagnosed patients (age: 51-63 years) were treated with intensive chemotherapy and autologous stem cell transplantation [9,10]. Relapsing patients (age: 46- 85 years) were treated with variable combinations of dexamethason, cyclophosphamide, thalidomide or bortezomib. The two patients with solitary plasmacytoma (age 40 and 60 yr) were treated with radiotherapy with and without intensive chemotherapy (table 2). 
Octreotide scintigraphy In all patients SRS was performed. In 5 patients a second scan was obtained after 3-5 months of treatment. The number of affected areas on the SRS varied between 1 and 12 per patient. The median uptake ratio was 2 .0 (range: 1.3-3.5.). Based on a comparison with the abnormalities seen by whole body radiography, we defined that SRS was only positive in lesions with a diameter of more than 1 cm. In four of the nine [44%, 95% confidence interval (Cl):0.12-0.77] newly diagnosed MM patients the SRS was positive, in the other 5 patients the SRS was normal (fig. 1). Two of these 5 patients had distinct abnormalities by whole body radiography. In both patients with solitary plasmacytoma, a positive SRS was obtained of the affected area which was confirmed by X-ray examination and CT-scanning. SRS was studied in 18 MM patients with relapsing disease. A positive SRS was shown in 15/18 (83%, 95% Cl: 0.66-1) of these patients. In 6 of the 15 (40%, 95% CI: 0.15-0 .60) evaluable patients the increase in SRS corresponded with new abnormalities on the whole body radiography, whereas in the other 9 patients (60%, 95% CI: 0.35-0.85) enhanced SRS activity was not accompanied by new abnormalities on the whole body radiography. 124 
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Figure 1: Representative abnormal SRS uptake of the distal femur 
in combination with the abnormal uptake on the standard skeleton 
(white arrow) .  No SRS uptake of the osteolytic lesion of the proximal 
femur (small black arrow) .  
Figure 2 :  Somatostatin receptors scintigraphy of 
the pelvis posterior view in patient with multiple 
myeloma in the iliac bone left, before treatment 
(A),  and after (B) .  The X-ray (anterior view) show 
a persistent osteolytic bone lesion (C). Arrow 
denotes the osteolytic lesion. 
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To verify that the increased octreotide uptake was related to disease activity, biopsies 
were performed of the affected areas (pelvis, clavicula) in four patients (no 1, 10, 1 1, 18). 
In all four cases histologically proven MM activity was present. 
To study the effect of treatment, follow-up scans were performed in five cases. Scans 
performed after 3-4 months of treatment demonstrated a complete disappearance of 
lesions in three patients and a decrease in two. These changes corresponded with reduced 
disease activity including declining paraprotein or FLC levels (table 3). 
Finally the somatostatin receptor expression sst3 was studied on biopsy material of 
patients with MM. It included bone marrow biopsy material and one extra-osseous 
manifestation of the MM. In total six patients were studied: four patients with a positive 
SRS scan and two patients with a negative scan. Three of four patients with a positive SRS 
showed positively stained MM cells, two of them showing strongly positive cells. One 
patient with a positive showed few strongly positive cells whereas no immunostaining 
was observed on the majority of the MM cells. One patient with a negative scan showed 
entirely negative tumour cells, and the other showed occasionally positive cells (table 
4, fig. 3). Although the series of patients is very small, we also looked for a possible 
relationship between the SRS results and tumour load in the biopsies, since negative 
SRS results might have been caused by a less prominent infiltrate. No such correlation 
was found (data not shown). 
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Table 3: Follow-up results of SRS scan after 3-months of treatment. 
Patient no Type of Paraprotiene level SRS Treatment 
Paraprot Upfront Follow up Upfront Follow up FLC- x. 204 2 + VAD 1 1  IgG- x. 37 4 + VAD 
1 2  IgG- x. 17 3 + Thalid/dexa 
1 8  FLC-A 885 68 + +/- Thalid/dexa 
20 FLC- x. 382 40 + +/- Thalid/dexa *Follow-up scan was performed 3 months after start of treatment with: thalidomide (thalid), dexamethason (dexa), or vincristin, adriamycin , dexamethason (VAD). Free light chain (FLC) serum level; normal range: FLC-A 4.4-32 mg/ml;  FLC-x 2.3-20 mg/ml .  
Table 4 :  Immunohistochemistry for somatostatin receptor subtypes sst3 and sst5 . 
Patients no SRS-scan SST3 SSTS 
1 Pos + + 
3 Ne + 
6 Ne + 
1 1  Pos ++ + 
23 Pos +++ + 




Several methods are available to demonstrate disease activity and bone lesions in 
patients with MM. Whole body radiography has been most frequently used so far and 
demonstrates the characteristic osteol ytic lesions in 60%-70% of the patients [ 1]. By 
using MRI scanning a further increase in skeletal abnormalities can be demonstrated. 
Recently, alternative techniques have been developed that make use of an increased 
metabolic activity of the malignant plasma cells. 18F-FDG-PET as well as 99mTc-sestamibi 
scanning have shown that in 80%-90% of the patients abnormal areas of increased uptake 
can be shown which are frequently associated with abnormal lesions on the whole body 
radiography [2,3,11,12]. In addition, there is evidence that the increased uptake of the 
99mTc-sestamibi correlates with other measurable parameters of disease activity including 
C-reactive protein, lactate dehydrogenase and B2-microglobulin [11,12]. 
Previous studies have shown that MM cell lines express functional receptors for sst2, 
sst3 and in particular sst5 and that in vitro growth of myeloma cells can be inhibited 
by somatostatin and its analogue octreotide [ 4]. Although the role of these receptors 
remains enigmatic in lymphoid cells, these findings provided us a rationale to study SRS 
in the clinical management of myeloma. It has been demonstrated that the currently used 
radiopharmaceuticals for somatostatin receptor targeting do not bind with high affinity 
to all presently known somatostatin receptor subtypes. They bind with very high affinity 
to sst2 and with somewhat lower affinity to sst3 and sst5 but not to sstl and sst4. 
The present study demonstrates that SRS is an alternative method to visualize in vivo 
MM activity. Although the number of patients with de novo disease is limited, the data 
in patients with relapsing disease suggest that SRS is more sensitive than other methods. 
The SRS was abnormal in 82% of the patients whereas conventional whole body 
radiography revealed new lesions in only 33% of the same patients. Histological analysis 
in six patients proved that the abnormal lesions as revealed by SRS were tumor related. 
Moreover, in most patients SRS-positive areas stained at least for the somatostatin 
receptor subtype sst3. Unfortunately, immunohistochemistry for sst2 and sst5 which was 
most widely expressed in myeloma cell lines was unsatisfactory [4]. 
Patients responsive on treatment demonstrated total or partial normalization of the 
abnormal uptake after 3-4 months of treatment, which correlated with a decline of other 
disease related parameters. A remarkable finding was the fact that a positive SRS was 
more frequently noticed in relapsing MM patients than in upfront patients. It is unlikely 
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SOMATOSTATIN RECEPTOR SCINTIGRAPHY MIGHT BE USEFUL FOR DETECTING SKELETON ABNORMALITIES IN PATIENTS WITH MULTIPLE MYELOMA AND PLASMACYTOMA that the difference is linked to the number of patients studied. Since we identified several MM cases with histologically massive, diffuse infiltrates that were mainly negative in immunohistochemistry, it is also unlikely that the differences in detection rate by SRS were caused by differences in growth pattern. It is more conceivable that an enhanced somatostatin receptor expression is shown in a more advanced state of the disease. This would be in line with the strong positive somatostatin receptor expression on MM cell lines which reflects also a more aggressive type of MM. Also in two patients with plasmacytoma a localized abnormal SRS could be shown. Although the number of patients studied is limited, these findings suggest that SRS might be a good alternative that verifies whether a localized disease is present. However, the skeletal abnormalities require a certain diameter. In our hands defects 3 1 cm were in general noticed by 
SRS. Smaller lesions were in general not shown on SRS. Improved localization of the abnormal SRS might further be obtained by combining it with the SPECT-CT scan. Also 99mTc-labelled somatostatin is a preferable diagnostic radionuclide for higher scan quality because of favourable decay properties (6 h half-life, gamma radiation of 140 KeV) that allow administration of a large dose, to yield high-resolution images, as well as lower cost and easy on-site availability by the 99Mo/99mTc generator in the clinic. PET labeled somatostatin analogue like 68Ga-DOTANOC are also an interesting option, due to the higher resolution of PET camera systems. In summary, the results demonstrate that SRS is a valuable tool to detect tumor activity in MM especially in patients with relapsing disease. 1 ?Q 
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Figure 3: a Normal pancreatic tissue showing positive islets and negative exocrine tissue (original 
magnification x200) . b Patient 1 with mainly negative but incidentally strongly positive tumour cells (see 
also the insert; original magnification x400) . c Patient 23 with strongly positive tumour cells . 
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Summary The bone marrow consists of different cell types that can be visualized by specific radiopharmaceuticals dependent on the cell type of interest. Different uptake and distribution patterns can be recognized which is not only determined by the used radiopharmacon but is also a reflection of the underlying disease. Imaging of the metabolic or proliferative activity of the bone marrow is recently developed by using 
18F-FDG or 18F-FLT. Therefore, the application of gamma- and PET camera techniques might be a useful approach in the diagnostic work up of patients with hematological disorders. In chapter 2 an overview is given of the current knowledge of bone marrow imaging by using different radiolabeled compounds. Radioisotopes for the use on gamma cameras have been used for several decades in nuclear medicine; however, they are restricted to image certain cell types of the bone marrow compartment. PET tracers can provide a more comprehensive assessment of the whole bone marrow compartment with a higher resolution with restricted image of a specific cellular function such as metabolic activity or proliferative activity. Distinct uptake patterns are described and the clinical applications in various hematological diseases are discussed. In chapter 3 the proliferative activity of the bone marrow compartment was studied in patients with various hematological disorders including myelodysplasia, myeloproliferative disease, myelofibrosis, multiple myeloma and aplastic anaemia by using 18F-FLT PET scan. This pyrimidine analog is phosphorylated by the enzyme thymidine kinase 1 (TKl ), which leads to intracellular trapping. TKl activity increases during DNA synthesis; therefore, 18F-FLT uptake is related to cellular proliferation. Patients with myelodysplasia and myeloproliferative disorders showed significantly higher FLT uptake by the bone marrow compartment compared to a control group. In contrast, patients with myelofibrosis and aplastic anaemia showed a significant decreased FLT uptake by the pelvis while a significant increased uptake by the liver and spleen was noticed in the case of myelofibrosis. FLT scans showed various degrees of bone marrow expansion with exception of patients with aplastic anaemia. No correlation was shown between FLT activities reflected by the SUV at the iliac crest with the proliferation rate of bone marrow cells as defined by the Ki-67 staining. Based on these findings 18F-FLT-PET provides visual and quantitative information on the entire bone marrow compartment and it may be beneficial in distinguishing various haematological disorders. 
SUMMARY AND GENERAL DISCUSSION In Chapter 4 the long term effects of the autologous stem cell transplantation (ASCT) was studied on the hematopoietic stem cell compartment by analyzing CD34+ bone marrow cells in detail 6-9 months following ASCT. This study included patients with relapsing lymphoma and myeloma treated with intensive chemotherapy and ASCT. A significantly increased percentage of phenotypically defined GMP was demonstrated of bone marrow CD34 + cells 6-9 months post-AS CT in con junction with a reduction in the phenotypicall y defined CMP fraction. In vitro cell cycle analysis revealed a significantly higher fraction of CD34+ cells in G2/S phase and a reduced percentage of cells in G 1 phase compared to normal CD34+ cells. 18F-FLT-PET demonstrated a significant increase in SUV measured at different points of the bone marrow compartment in the post-transplantation patients. In addition, a significant expansion of the bone marrow compartment was noticed. These data demonstrate an enhanced proliferation rate of bone marrow cells defined with in vitro and in vivo assays following ASCT even when the peripheral blood cells have been normalized to great extent. 
Chapter 5 deals with bone marrow visualization in patients with aplastic anemia by using 18F-FLT-PET. Patients (n=l 7) were studied at presentation or at relapse or after having achieved a partial of complete normalization of peripheral blood cells following immunotherapy or allogeneic stem cell transplantation. The findings were compared with the findings of the bone marrow biopsy. A significant reduced uptake of 18F-FLT by the pelvis was noted in untreated or relapsed patients. Patients in complete remission following allogeneic stem cell transplantation demonstrated a homogenous uptake throughout the skeleton while patients in partial remission following immunotherapy showed variable areas of increased uptake (hot spots) including the peripheral skeleton. In almost all the patients a normal uptake of the spleen was shown. These data demonstrate that 18F-FLT-PET provides a highly distinctive picture that might be helpful to distinguish aplastic anemia patients from other hematological bone marrow disorders. In addition, it might be helpful to monitor the treatment response. 
Chapter 6 describes the effect of radiotherapy and chemotherapy on the bone marrow function in patients with laryngeal carcinoma and non-seminomatous testicular germ cell tumors. Patients with laryngeal carcinoma receiving local radiotherapy (70 Gy) were studied by 18F-FLT-PET before and after radiotherapy with special focus on the cervical region. Whole body 18F-FLT-PET images were also assessed in patients with non seminomatous testicular germ cell tumors before and 4 months after the final chemotherapy consisting of 4 courses of bleomycin, cisplatin, and etoposide. A 
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significant decrease in 1 8F-FLT uptake was observed in the cervical region of the adjacent 
bone marrow compartment after radiotherapy in all laryngeal carcinoma patients. The 
radiotherapy field was inversely related to the 1 8F-FLT uptake (SUVmax 3.0 ± 1.28 and 
after radiotherapy 1.8 1  ± 0.72 (p= 0.0017). This study shows that the 1 8F-FLT-PET can 
be used to visualize the effect of therapy-related bone marrow toxicity in patients being 
treated for malignancy, and might be a tool to define the residual hematopoietic activity. 
Chapter 7 shows the utility of 1 8F-FLT-PET to detect extramedullary hematopoiesis in 
a patient presenting with a history of hemoglobin-E and �-thalassemia. Extramedullary 
hematopoiesis (EMH) is a rare disorder defined as the localization and probably 
production of myeloid and erythroid cells outside of the bone-marrow cavity. In this 
patient a large mass was identified. The MRI could not differentiate between lymphoma 
and EMH. Therefore an 1 8F-FLT PET was performed and demonstrated a large mass 
bilateral and paravertebral in the thorax with an elevated SUV suspect of EMH. These 
findings demonstrated that 1 8F-FLT PET is an additional , non-invasive technique for the 
diagnosis of EMH. 
Chapter 8 demonstrates the additional value of somatostatin receptor scintigraphy (SRS) in patients with multiple myeloma (MM). In 60%-70% of the patients with MM 
osteolytic defects are identified by X-ray examination. These defects persist following 
treatment and no clear distinction can be made whether vital tumor cells are present in 
these lesions. Several small studies have demonstrated that FOG-PET might identify 
the metabolic activity of the malignant plasma cells. 99mTc sestamibi scanning can show 
increased uptake in the MM lesions. In vitro studies with plasma cell lines have shown 
that the somatostatin receptor is expressed on malignant plasma cells. We explored this 
feature with imaging of MM using SRS. SRS was performed in newly diagnosed and 
relapsing MM, and plasmacytoma. In addition in five patients SRS scans were repeated 
after 3-5 months of treatment. A positive SRS was found in 44% of newly diagnosed 
MM patients. Patients with solitary plasmacytoma showed in all cases a positive SRS. 
The relapsing group showed a positive SRS in 83% of these patients. 60% of the positive 
SRS with an enhanced SRS activity was not accompanied by new abnormalities on the 
whole body radiography. The follow up SRS scans revealed a complete disappearance of 
lesions in three patients and a partial response in two. These changes corresponded with 
reduced disease activity. In conclusion these data demonstrate that SRS can be used as an 
alternative method to detect disease activity in malignant plasma cell disorders. 
SUMMARY AND GENERAL DISCUSSION 
General discussion and Future perspective 
Gamma camera radiopharrnaceuticals evaluates bone marrow compartment based on the 
target cell system (reticulo-endothelial system, the erythroid and myeloid bone marrow 
compartment). Limitations in resolution are a common draw back of gamma camera 
systems. In contrast PET permits the evaluation of the whole bone marrow compartment 
which might include cellularity and metabolic activity. Better resolution and more 
accurate quantification of PET systems results in better image quality and more accurate 
quantification of bone marrow activity that may be important for monitoring treatment 
response. In this thesis we demonstrate that 18F-FLT uptake reflects in a certain degree the 
proliferative activity of the bone marrow compartment which provides a better tool for 
monitoring therapy response. Several patterns of bone marrow uptake can be identified 
depending on the hematopoietic activity and the underlying disorder. Also discordance 
between bone marrow biopsy and peripheral blood findings might be seen as in the case 
of aplastic anemia due to patchy areas of aberrant hematopoiesis in the bone marrow 
compartment. 
In patients following ASCT, high uptake of 18F-FLT by the bone marrow compartment 
was demonstrated which reflected a higher proliferative activity. In vitro cell cycle 
analysis of CD34+ cells confirmed these results. These findings were noticed even 
when the peripheral blood cell counts have been normalized in great extent. It is 
conceivable that these findings correlate with a replicative stress response related to the 
transplantation procedure whereby a limited number of stem cells have been infused that 
have to replenish the total stem and progenitor compartment. In addition, an enhanced 
shortening of the telomeres and an enhanced aging process might be contributing and 
resulting in a shift to more committed cells that have the intrinsic property of a higher 
proliferative activity [ I ]. 
In the future new techniques might be developed and used to visualize cell death. 
Annexin V is expressed by dying (apoptosis or necrotic) cells [2]. In the early phases 
of apoptosis, cells can be directly engulfed by phagocytes. Phagocytes identify their 
targets by the prolonged extensive exposure of the anionic membrane phospholipid 
phosphatidylserine (PS) on the surface of unwanted cells. There is evidence that annexin 
V binds to PS exposed on the cell surface and forms a protein crystal followed by 
rapid internalization via a unique pathway of pinocytosis . 99mTc-labeled annexin V was 
proposed as a method to study tumor behavior and therapy response [3]. Since PET has 
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major advantages for quantitative imaging, several approaches have been developed to 
label annexin V with 18F [ 4 ,5]. 18F-annexin V PET may be of use to study the effectiveness 
of the applied therapy in leukemia, myeloma or myeloproliferative disorders. A major 
challenge will be to define the optimal time point of imaging in particular in the setting 
of defining tumor response following chemotherapy or radiotherapy. Blankenberg et 
al . reported an increased annexin V uptake by bone marrow cells as early as 8 hours 
after cyclophosphamide treatment and lasted approximately 2 days [6]. Animal models 
might be of great help to perform these preclinical studies. For studies of steady state 
hematopoiesis a different approach might be used. 
CD66 antigen is expressed at the cell surface of mature myeloid cells. Anti-CD66 
monoclonal antibodies (mAbs) labelled with beta-emitting nuclides ( 188Re and 90Y) has 
already been introduced and is suited as myelo-ablative radioimmunotherapy prior to 
stem cell transplantation in acute leukemia [7]. Therefore , it is of interest to determine 
the CD66 distribution in the bone marrow compartment to assess therapy response 
following treatment. 1 8F-Immuno-PET may, therefore, be a useful tool in the future. 
New imaging tools with 89Zr-bevacizumab have become available in solid tumors for 
visualization the neovascularisation of the affected organ [8]. Vascular endothelial 
growth factor (VEGF) has a prominent position in triggering neoangiogenesis [9]. 89Zr­
bevacizumab PET provides a noninvasive tool to monitor the expression of tumor VEGF 
as well as response on treatment [10]. Also in haematological disorders this approach 
might be an attractive option to visualize the enhanced bone marrow microvessel 
density for example in myeloma and leukemia and monitor the response on anti-VEGF 
treatment[ 1 1 ]. 
To date, somatostatin receptor scintigraphy (SRS) using 1 1 1ln-pentetreotide a radiolabelled 
analogues of somatostatin have been used for imaging and treatment in neuroendocrine 
tumors (NETs). Recently 68Ga- labelled octreotide analogues are introduced to image 
somatostatin receptors (sstr) in NETs [12,13]. Peptide receptor radionuclide therapy 
(PRRT) with somatostatin analogues 90Y-DOTATOC and 177Lu-DOTATATE has been 
used in NETs [ 14]. SSTR has also been reported to be highly expressed in other 
malignancy, including lymphomas [15]. We noted sstr overexpression in MM; however, 
only subtypes 3 and 5 are studied in these patients. Therefore, it is interesting in the 
future to study all sstr subtypes especially sstr2 in more patients and possible applying of 
PRRT with somatostatin analogues 90Y-DOTATOC and 177Lu-DOTATATE. In addition , 
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68Ga PET is a possible future technique in the diagnosis of MM as it provides a better 
resolution and more accurate quantification thereby increasing diagnostic accuracy. 
Cancer cells frequently exhibit increased glycolysis [ 16]. Mitochondrial malfunction and 
hypoxia in the tumor microenvironment are considered two major contributing factors 
[17]. However, whether the increase of glycolytic activity in cancer cells is mainly due to 
inherent metabolic alterations or due to anaerobic micro environment in the tumor tissues 
remains controversial [ 18]. Insufficient blood supply can occur due to the rapid expansion 
of the tumor mass. Limitation of the availability of oxygen for use in mitochondrial 
respiration up-regulates the glycolytic pathway which is mediated by increased 
expression of various kinases required for glycolysis. The metabolic consequence of the 
mitochondrial malfunction and hypoxia is increased glycolysis to provide energy supply 
and thus renders cancer cells highly dependent on this metabolic pathway for survival 
[19]. A number of PET radiopharmaceuticals are recently developed to image hypoxia. 
Intercellular trapping by reductive mechanisms occurs due to low oxygen tension in 
hypoxic tissue. [ 18F]Fluoromisonidazole-3-fluoro-l-(2 °-nitro-1 °-imidazolyl)-2-
propanol { 18F-MISO) and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone (64Cu-ATSM), 
and the recently introduced [ 18F]fluoroazomycinarabinoside ( 18F-FAZA) can potentially 
be used to image bone marrow hypoxia as non-invasive method [20,21]. Bone marrow 
uptake of 18F-FAZA may potentially increase during hypoxic circumstances. This might 
be attractive approach to define whether the increased uptake of FDG-PET by myeloma 
cells is a reflection of enhanced glycolysis in association with hypoxia. Furthermore, bone 
marrow biopsy material might be of importance to demonstrate whether the enhanced 
glucose uptake by the myeloma cells is associated with an enhanced expression of glut 
-1 and glut-3 [22]. 
In summary these data show that different aspects of the bone marrow can be non­
invasively imaged by using a variety of radiopharmaceuticals. Selective bone marrow 
biopsy can be achieved after bone marrow land marking using nuclear medicine imaging. 
In addition the imaging techniques might be used during and following specific therapies 
dependent on the underlying haematological disorder. 
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CHAPTER 1 0  
Nederlandse samenvatting 
Het beenmergcompartiment kan gevisualiseerd warden door gebruik te maken van spe­
cifieke radiofarmaca die verschillende celtypen binnen dit geheel kunnen herkennen . 
De afbeelding ervan vindt plaats met gammacamera's en PET-technieken. Verschillende 
distributiepatronen en intensiteiten kunnen warden gezien , afhankelijk van het onderlig­
gend ziektebeeld van het beenmerg. De toepassing van deze technieken kan van belang 
en aanvullend zijn in het diagnostische proces van patienten met hematologische aan­
doeningen. Dit wordt nader toegelicht in hoofdstuk 2. 
In hoofdstuk 2 wordt een overzicht gegeven van de huidige kennis over been­
merg beeldvorming met verschillende gelabelde radioisotopen. Radioistopen voor 
de gammacamera's zijn al enkele decennia in gebruik in de nucleaire geneeskun­
de en warden ingezet om bepaalde functies van het beenmerg te onderzoeken. PET­
camera's geven in vergelijking met de gammacamera een nauwkeuriger beeld van 
het hele beenmerg compartiment met een hogere resolutie waarbij ook een meer 
specifieke cellulaire functie kan warden onderzocht afhankelijk van de gebruik­
te PET radiofarmacon. Verschillende opnamepatronen zijn zichtbaar gemaakt en 
de klinische toepassingen bij diverse hematologische ziekten warden besproken. 
In hoofdstuk 3 is de in vivo proliferatieve activiteit van het beenmerg compartiment 
bestudeerd met behulp van de 18F-FLT-PET scan bij patienten met verschillende hemato­
logische aandoeningen, zoals myelodysplasie , myeloproliferatieve ziekten inclusief my­
elofibrose, multipel myeloom en aplastische anemie. Patienten met myelodysplasie en 
myeloproliferatieve ziekten toonden een significant hogere 18F-FLT opname in het been­
merg in vergelijking met de controle groep. Dit in tegenstelling tot patienten met myelo­
fibrose en aplastische anemie die een significante lagere 18F-FLT opname vertoonden in 
het beenmerg maar een aanzienlijk hogere opname in de lever en de milt in het geval van 
myelofibrose. Er bleek geen correlatie te bestaan tussen de 18F-FLT activiteit in het bekken 
en de Ki-67 activiteit (proliferatie marker) in het beenmergaspiraat. Gebaseerd op deze 
bevindingen kan 18F-FLT-PET behulpzaam zijn in het onderscheiden van verschillende 
hematologische aandoeningen en daardoor van waarde zijn in het diagnostisch proces. 
In hoofdstuk 4 zijn de lange termijn effecten van autologe stamceltransplantatie (ASCT) 
onderzocht op het hematopoietische stamcel compartiment door de beenmergcellen 
zowel in-vitro als in-vivo te onderzoeken. De studie omvatte patienten die behandeld 
waren voor een recidief lymfoom of multipel myeloom met intensieve chemotherapie 
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en autologe stamcel re1nfusie. 6-9 maanden na de transplantatie zijn de onderzoekin­
gen verricht. Faes analyse van de beenmergcellen liet een verschuiving in het proge­
nitor compartiment zien. Dit ging samen met een significante hogere delingsfractie in 
de CD34+ celfractie. In vivo experimenten met 1 sF-FLT-PET beeldvorming bevestigden 
deze gegevens. 
Hoofdstuk 5 is 1sF-FLT-PET gebruikt om het beenmerg compartiment te onderzoeken 
bij patienten met een aplastische anemie (AA). Recent gediagnosticeerde AA patien­
ten, patienten met een recidief AA en patienten na behandeling zijn onderzocht. De 
bevindingen zijn vergeleken met de gegevens van het beenmergbiopt. Een aanzienlijk 
verminderde opname van 1sF-FLT in het bekken werd waargenomen bij patienten met 
actieve AA ziekte. Patienten in volledige remissie na allogene stamceltransplantatie 
toonden een homogene opname in het skelet terwijl patienten in gedeeltelijke remis­
sie na immunotherapie een sterke variabele opname (hot spots) vertoonden, inclusief 
opname in het perifere skelet. Deze gegevens tonen aan dat AA middels 1 sF-FLT-PET 
van andere hematologische beenmergaandoeningen kan warden onderscheiden. Boven­
dien zou het van waarde kunnen zijn om de respons op de behandeling te vervolgen. 
Hoofdstuk 6 beschrijft het effect van radiotherapie en chemotherapie op de 1 sF-FLT 
opname van het beenmerg compartiment . De hals regio bij patienten met een larynxcar­
cinoom die behandeld zijn met 70 Gy radiotherapie toonde geen 1sF-FLT opname meer 
6 maanden na de behandeling. Dit in tegenstelling tot patienten die behandeld zijn met 
chemotherapie voor non-seminomateuze testiculaire kiemceltumoren. Vier maanden na 
de laatste chemotherapie was er geen verschil met de controle groep suggererend <lat 
deze vorm van cbemotberapie geen blijvend effect beeft op de cycliscbe activiteit van 
bet bematopoietisch beenmerg compartiment. 
Hoofdstuk 7 toont de waarde van 1sF-FLT-PET aan om lokalisaties van extramedullaire 
hematopoiese (EMH) op te sporen. Een patient bekend met bemoglobine-E (3-tbalassemie 
wordt gepresenteerd met een grate massa bilateraal en paravertebraal in de borstbolte. 
De MRI kon geen duidelijk onderscbeid maken tussen lymfoom of EMH. De vervolgens 
uitgevoerde 1sF-FLT-PET toonde verboogde opname van 1sF-FLT aan in het proces bila­
teraal en paravertebraal in de thorax dat qua intensiteit vergelijkbaar was met de opname 
in beenmerg en milt hetgeen verdacbt is voor EMH. 
Hoofdstuk 8 beschrijft de waarde van somatostatine receptor scintigrafie (SRS) bij 
patienten met een multipel myeloom (MM) . In 60% -70% van de patienten met MM 
warden osteolytiscbe afwijkingen ge1dentificeerd door bet verricbten van rontgen on-
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derzoek van bet skelet. Deze afwijkingen blijven bestaan na  de bebandeling waardoor 
er geen goed onderscheid gemaakt kan warden tussen vitale tumorcellen versus oude 
restafwijkingen in bet skelet. Somatostatine receptoren zijn in bet verleden al aange­
toond op maligne plasmacellen door middel van immunohistochemische technieken. De 
resultaten van bet huidige onderzoek tonen aan dat SRS goed gebruikt kan warden om 
ziekteactiviteit bij patienten met een recidief MM aan te tonen. Een positieve SRS werd 
gevonden in 44% van de nieuw gediagnosticeerde MM patienten, bij alle patienten met 
een solitair plasmacytoom en in 83% van de patienten met hemieuwde ziekteactiviteit. 
De follow-up SRS-scans bij vijf patienten liet een volledige verdwijning zien van de lae­
sies bij drie patienten en een gedeeltelijke respons bij twee patienten. Deze wijzigingen 
correspondeerden met een verminderde ziekteactiviteit. Deze gegevens duiden erop dat 
SRS kan warden gebruikt als een altematieve methode om ziekteactiviteit bij maligne 
plasmacel aandoeningen te detecteren. 
Samenvattend lijkt bet dat 1 8F-FLT-PET een waardevolle techniek is om verschillende 
hematologische aandoeningen van het beenmerg compartiment te diagnosticeren en 
mogelijk naar de toekomst te gebruiken als follow-up parameter tijdens of na de be­
handelingsfase. Toekomstige ontwikkelingen zijn het afbeelden van nieuwe targets bij 
hematologische ziektebeelden, zoals specifieke receptoren en celprocessen. Te denken 
valt aan angiogenese, waarbij de vaso-endotheliale groei factor (VEGF) een belangrijke 
rol speelt. Dit kan bijvoorbeeld met 89Zr-bevacizumab PET afgebeeld warden. Een ander 
belangrijk proces is apoptosis (geprogrammeerde celdood). Dit kan met radioactief gela­
belde annexine-V warden afgebeeld. Bepaalde bematologische aandoeningen zoals leu­
kemie, multipel myeloom, en myeloproliferatieve aandoeningen, gaan na behandeling 
in apoptose. 99mTc-annexine SPECT zou hierin een rol kunnen spelen voor het monitoren 
van de behandeling. Een aantal PET radiofarmaca zijn ook ontwikkeld om bypoxie af 
te kunnen beelden in maligne tumoren. Weinig hierover is bekend bij de verschillende 
bestudeerde aandoeningen. 
Somatostatine receptor scintigrafie kan gebruikt warden als een altematieve methode om 
ziekteactiviteit te detecteren met name bij patienten met hemieuwde ziekte activiteit van 
het multipel myeloom. 68Ga-gelabelde somatostatine PET is mogelijk een nog nauwkeu­
riger techniek om multipele myeloom activiteit aan te tonen, vanwege de hogere resolu­




99mTc-AGAb t 1 11n-CL 3 
64Cu-ATSM AA ALL AML ASCT BFU-E BM CFC CFU-GM CI CML CMP CR CT DLBCL DNA EHM 
FDG FLC ABBREVIATIONS [ 1 8F]Fluoromisonidazole-3-fluoro-l -(2 '-nitro-1 '-imidazolyl)-2-propanol [ 1 8F]fluoroazomycinarabinoside 64Cu-diacety l-bis(N4-methy lthiosemicarbazone 99mTc-labelled antigranulocyte antibodies 1 1 1lndium-chloride 64Cu-diacetyl-bis(N4-methylthiosemicarbazone Aplastic anemia acute lymphoblastic leukemia acute myeloid leukemia autologous stem cell transplantation burst forming unit erythroid bone marrow colony forming cell Colony forming unit -granulocyte macrophage confidence interval chronic myeloid leukemia common-myeloid progenitor complete response computed tomography diffuse large B-cell lymphoma deoxyribonucleic acid Extramedullary hematopoiesis Fluorodeoxy glucose free light chain 
147 
ABBREVIATIONS FLT G-CSF GMP GM-CSF HA HGF HL HSCs mAbs MBq MDS MEP MeV MF MM MPDs MRI NCA-95 NETs NSCLC PET 
PR 
PSA 
PV RES ROI 
RT SPECT 
SRS sstr SUV TKl VEGF WBC 3-fluoro-3-deoxy-L-thymidine granulocyte colony-stimulating factor granulocyte-macrophage progenitor granulocyte-macrophage colony-stimulating factor Hemolytic anemia hematopoietic grow factor Hodgkin Lymphoma hematopoietic stem cells monoclonal antibodies megabecquerel Myelodysplastic syndromes megakaryocytic-erythroid progenitor mega electron volt myelofibrosis Multiple myeloma Myeloproliferative diseases magnetic resonance imaging non-specific cross reacting antigen 95 neuro-endocrine tumors non-small cell lung cancer Positron Emitting Tomography partial response prostate specific antigen Polycythemia vera reticulo-endothelial system region of interest radiotherapy Single Photon Emission Computed Tomography Somatostatin receptor scintigraphy somatostin receptor standardized uptake value thymidine kinase 1 vascular endothelial growth factor white blood cells 
Dankwoord 
Dankbaarheid is bet geheugen van bet hart (Gospel Doctrine) Allereerst wil ik mijn promotie team bedanken. Mijn promotor Prof. dr. E. Vellenga. Beste Edo, bedankt voor de mogelijkheid om het promotieonderzoek te mo gen verrichten. 1k heb grate be wondering voor de manier waarop jij de zaken regelt. Bedankt voor je continue, nauwkeurige en wetenschappelijke begeleiding in de afgelopen jaren. 1k wil je daamaast nog bedanken voor jouw zeer gedetailleerde commentaar op mijn stukken en voor jouw advies, steun, vertrouwen en positieve feedback. Mijn copromotor dr. R.H.J.A. Slart. Beste Riemer, jouw enorme enthousiasme en positieve instelling heeft me menig keer geholpen om door te zetten. Je hebt altijd een grote rol gespeeld in mijn begeleiding. Je hebt mij echt door de laatste loodjes heen gesleept en mijn stukken ongekend snel van commentaar en correcties voorzien. Mijn tweede promotor Prof. dr. R. Dierckx, beste Rudi, bij dezen wil ik je bedanken voor het bieden van de mogelijkheid om te promoveren binnen de afdeling Nucleaire Geneeskunde. Bedankt voor bet vertrouwen en de stimulerende gesprekken die we de afgelopen jaren gevoerd hebben. Daamaast wil ik Prof. dr. P.L. Jager bedanken voor de begeleiding tijdens mijn opleiding en alle hulp bij het opzetten van het eerste onderzoek van dit proefschrift. 1k kijk met veel plezier terug op deze periode. De leden van de leescommissie, Prof. dr. P.M. Kluin, Prof. dr. P.H. Elsinga en Prof. dr. C. van de Wiele wil ik bedanken voor de tijd en moeite die ze hebben genomen om mijn proefschrift te beoordelen. 
1L1.Q 
DANKWOORD 
De stafleden van de afdeling NGMB wil ik bedanken. Jan Pruim en Adrienne Brouwers , 
beste Jan en Adrienne, bedankt voor jullie supervisie tijdens mijn opleiding en de vele 
fijne gespreken. Jan , bedankt voor jouw technische ondersteuning bij bet afronden van 
bet review artikel. Andor Glaudemans, Andor de samenwerking met jou was prettig en 
vlot hetgeen erg heeft bijgedragen aan bet vlotte afronden van bet schrijven en publiceren 
van bet review artikel. 
Veel dank ben ik verschuldigd aan de MNW-ers van bet PET centrum in bet bijzonder 
Johan , Remko en Paul. Beste Paul , je bent altijd enthousiast , bedankt voor de moeite en 
de tijd om de PET scans keurig en op tijd naar mijn toe te zenden. Ook de overige MNW­
ers van de afdeling NGMB wil ik bedanken voor de prettige samenwerking. 
Sylvia Koster en Ineke ten Have, bedankt voor jullie ondersteunende hulp en bet regelen 
van alle zaken o.a. gesprekken met mijn promotie team. 
Mijn dank gaat ook uit naar mijn collega's bij bet Ziekenhuisgroep Twente , Clemens 
Ticheler, Marc Zuijdwijk en Nils Wagenaar. Bedankt voor de vriendelijke en uitstekende 
werksfeer, en de goede organisatie zodat ik nog aan mijn proefschrift heb kunnen werken. 
Tevens wil ik de MNW-ers en de secretaresses van afdeling nucleaire geneeskunde 
Ziekenhuisgroep Twente bedanken voor de gezellige sfeer. 
Bart Schot , internist. Beste Bart, we hebben bet eerste artikel van dit proefschrift samen 
afgerond onder begeleiding van Prof. Dr. E. Vellenga en Prof. dr. P.L. Jager. Dit was een 
mooi begin van mijn promotietraject. Gelukkig werken we allebei nog steeds in Twente. 
Mijn paranimfen, Ha Phan en Klaas Pieter Koopmans , ik waardeer jullie hulp en 
steun. Ik ben blij dat jullie mijn paranimfen willen zijn. Ik vergeet nooit de prachtige 
opleidingsperiode. Ik hoop dat we contact blijven houden en elkaar regelmatig zien. 
Beste Ha, nog bedankt voor bet nalezen van mijn proefschrift. 
B v. Beste Klaas Pieter, ik vond bet een eer dat ik toen jouw paranimf mocht zijn. Bedankt 
dat je nu mijn paranimf wilt zijn. 
DANKWOORD Mijn fijne collega's tijdens mijn opleiding in het UMCG, Mohammed Dal, Silvia Eshuis en later Niels Veltman wil ik tevens bedanken. Ik kijk met veel plezier terug op deze periode. De grootste bran van inspiratie waar ik mijn kracht uitput is mijn familie en gezin. Lieve familie, ik weet <lat jullie erg blij zijn, echter door de moeilijke omstandigheden in Irak krijg ik een pijnlijk gevoel <lat niemand van jullie mijn promotie kan meemaken. 1k kan het goed voelen hoe mijn moeder elke <lag voor mij bidt. Broers en zusters bedankt voor jullie steun vooral emotioneel. Daarnaast wil ik mijn gezin bedanken, Hind en mijn vrolijke schatjes, Tasnim en Muhammed. Bedankt voor jullie begrip en steun. Mijn grootste angst is <lat als het boekje klaar is, ik er pas achter kom <lat ik iemand vergeten heb te bedanken. Bij dezen, alsnog bedankt ! 
1 " 1  

Curriculum Vitae 
Ali Agool werd op 14 juli 1967 geboren te Bagdad. Het VWO diploma werd bebaald in 
1985. 
In betzelfde jaar werd begonnen met de studie geneeskunde aan de AI-Mustansiriya 
Universiteit te Bagdad. Het artsexamen werd bebaald in 1991. In 1992 begon bij als 
arts-assistent in Ibn Alnafis ziekenbuis te Bagdad. Na zijn komst naar Nederland in 
1994 studeerde bij Nederlands en beeft bij zijn co-scbappen gevolgd in bet UMCG te 
Groningen. In november 1999 bebaalde bij zijn vereiste tweede artsdiploma. Hij beeft in 
2002 gewerkt als arts -assistent op de afdeling Cbirurgie van bet TweeSteden ziekenbuis 
in Tilburg. Vervolgens als arts-assistent op de afdeling Interne Geneeskunde van bet 
Groene Hart Ziekenbuis te Gouda. Van september 2002 tot september 2006 volgde bij 
de opleiding tot nucleair geneeskundige op de afdeling Nucleaire Geneeskunde in bet 
UMCG met als opleider Prof. dr. P.L. Jager. Vanaf oktober 2006 tot beden werkt bij als 
nucleair geneeskundige in bet Ziekenbuisgroep Twente. Hij kreeg in 2006 een promotie­
aanstelling als onderzoeker bij afdelingen Nucleaire Geneeskunde en Hematologie van 
het UMCG. Ali Agool is getrouwd met Hind R. Karim en beeft 2 kinderen. 
153 
1 1  Ot)-1.f Ot' 
